



**HAL**  
open science

## Autoinflammatory diseases: State of the art

Sophie Georquin-Lavialle, Antoine Fayand, François Rodrigues, Claude Bachmeyer, Léa Savey, Gilles Grateau

### ► To cite this version:

Sophie Georquin-Lavialle, Antoine Fayand, François Rodrigues, Claude Bachmeyer, Léa Savey, et al.. Autoinflammatory diseases: State of the art. La Presse Médicale, 2019, 48, pp.e25 - e48. 10.1016/j.lpm.2018.12.003 . hal-03486058

**HAL Id: hal-03486058**

**<https://hal.science/hal-03486058>**

Submitted on 20 Dec 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

LPM

QMR Autoinflammatory diseases

### **Autoinflammatory diseases: state of the art**

#### **Authors:**

Sophie Georgin-Lavialle<sup>1,2</sup>, Antoine Fayand<sup>1</sup>, François Rodrigues<sup>1</sup>, Claude Bachmeyer<sup>1</sup>, Léa Savey<sup>1</sup>, Gilles Grateau<sup>1,2</sup>.

#### **Affiliations:**

<sup>1</sup>Sorbonne Université, AP-HP, Hôpital Tenon, Service de médecine interne, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), F-75020, Paris

<sup>2</sup>INSERM UMRS\_933, Hôpital Trousseau, Assistance Publique Hôpitaux de Paris, Université Pierre et Marie Curie (UPMC)-Paris 6, Paris, France

#### **Corresponding author:**

Dr Sophie Georgin-Lavialle

Internal medicine department, Tenon hospital, 4 rue de la Chine, 75020 Paris, France

Sorbonne Paris Université, Assistance Publique-Hôpitaux de Paris.

E-Mail: [sophie.georgin-lavialle@aphp.fr](mailto:sophie.georgin-lavialle@aphp.fr)

## **Key points**

Monogenic autoinflammatory diseases are characterized by genetic abnormalities encoding proteins involved in innate immunity.

Their main feature is the presence of peripheral blood inflammation in crisis without infection. The best-known autoinflammatory diseases are mediated by interleukin 1 and consist in the 4 following diseases: familial Mediterranean fever, cryopyrinopathies, TNFRSF1A-related intermittent fever, and mevalonate kinase deficiency.

In the last 10 years, many other autoinflammatory diseases have been discovered, especially thanks to the progress in genetics.

The diagnosis of autoinflammatory disease is mainly based on anamnesis, presence of peripheral blood inflammation during attacks and genetic analysis which are more and more sensitive.

### **QMR Autoinflammatory diseases**

#### **Editorial**

Gilles Grateau, France

#### **Autoinflammatory diseases : state of the art**

Sophie Georgin-Lavialle et al, France

#### **How to prescribe a genetic test for the diagnosis of autoinflammatory diseases ?**

Dorota Monika Rowczenio et al, United Kingdom

#### **Familial Mediterranean fever**

Huri Ozdogan et al, Turkey

#### **Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis syndrome – PFAPA syndrome**

Per Wekell, Sweden

## **Abstract**

Autoinflammatory diseases are characterized by innate immunity abnormalities. In autoinflammatory diseases (AID), inflammatory blood biomarkers are elevated during crisis without infection and usually without autoantibodies. The first 4 described AID were familial Mediterranean fever, cryopyrin-associated periodic fever syndrome (CAPS) or *NLRP3*-associated autoinflammatory disease (*NLRP3*-AID), mevalonate kinase deficiency (MKD) and *TNFRSF1A*-receptor associated periodic fever syndrome (TRAPS). Since their description 20 years ago, and with the progresses of genetic analysis, many new diseases have been discovered; some with recurrent fever, others with predominant cutaneous symptoms or even immune deficiency. After describing the 4 historical recurrent fevers, some polygenic inflammatory diseases will also be shortly described such as Still disease and periodic fever with adenitis, pharyngitis and aphtous (PFAPA) syndrome. To better explore AID, some key anamnesis features are crucial such as the family tree, the age at onset, crisis length and organs involved in the clinical symptoms. An acute phase response is mandatory in crisis.

## 1-INTRODUCTION

Since the term autoinflammation was coined, several definitions and therefore classifications of autoinflammatory diseases (AID) have been proposed (1). We will retain here the definition of auto-inflammatory diseases as disease with clinical and biological inflammatory component and linked to an anomaly of innate immunity (2). Many advances in genetics over the past decade have led to the discovery of several new monogenic AID each year. The best-known subgroup because first described is the "hereditary recurrent fevers" subgroup, including 4 historical interleukin (IL)-1 dependent diseases: familial Mediterranean fever (FMF), the most frequent AID, cryopyrinopathies which form a spectrum of diseases related to *NLRP3* mutations (*NLRP3*-associated autoinflammatory disease or *NLRP3*-AID), mevalonate kinase deficiency (MKD) and TRAPS syndrome (Tumor Necrosis Factor type 1A Receptor-Associated Periodic fever Syndrome) (1,3).

Interestingly, genetic discoveries in recent years have shown that some monogenic diseases have a different clinical expression depending on the site of the mutation in the gene; indeed, the clinical spectrum of the diseases associated to mutations of the following genes *MEFV*, *NLRC4*, *NOD2*, *PSTPIP1* has been extended (4–8). Another advance in genetics is the discovery of patients displaying somatic mutations of genes associated with AID either when the disease occurs late in life or if it occurs early in life but among these patients, only a fraction of cells is mutated (9–14). This article aims to summarize the main AID, their pathophysiology and the treatment's principles, and to propose a diagnostic approach.

## 2-MAIN PATHOPHYSIOLOGICAL PATHWAYS INVOLVED IN AID

The innate immune response has evolved to protect organisms from exogenous and endogenous hazards that threaten, damage or destroy the organism (figure 1). The goal of the immune response is to eliminate or sequester the source of the disturbance and restore tissue function and homeostasis. Innate immune system uses a limited number of receptors recognizing exogenous and endogenous molecular units; when the pathway is activated it leads to the production of proinflammatory cytokines and chemokines to recruit immune cells into tissues and coordinate tissue defense. To avoid inappropriate and damaging responses, there are many regulatory mechanisms. Autoinflammatory diseases are caused by abnormalities that can occur at each stage of the immune response and its regulation.

Some of the autoinflammatory diseases are due to an exaggerated detection of extracellular and intracellular danger signals. The best examples are inflammasomopathies due to a genetic

abnormality of a component of a cytosolic receptor responsible for facilitated or permanent production of pro-inflammatory cytokines (15). Inflammasomes are protein platforms, which in response to danger signals will recruit caspase 1, capable of cleaving pro-IL-1 $\beta$  and pro-IL-18, and result in secretion of IL-1 and IL-18 pro-inflammatory cytokines. Inflammasomopathies are diseases associated with mutations of inflammasomes: pyrin (FMF, PAAND), NLRP3 (CAPS), NLRC4, NLRP12; in these diseases, the role of interleukin-1 is major (15).

Ubiquitination is the process which leads to the specific and regulated binding of one or more ubiquitin molecules to a target protein. The main function of this post-translational modification are the recognition and destruction of the protein thus labeled by the proteolytic complex of the proteasome. Ubiquitination involves enzymes called ligases E1, E2 and E3. This highly dynamic process is reversible: this so called deubiquitination is the process by which Ubiquitin chains are removed from substrates modified by a class of enzymes known as deubiquitinases (DUB) (16,17). There are about 100 proteases with DUB activity including the proteins A20 and OTULIN, which function as negative regulator of NF- $\kappa$ B signaling; the linear assembly complex of the linear ubiquitin chain (LUBAC) - is a set of proteins: HOIP, HOIL-1 and SHARPIN which, together with the E3 ligase, helps to maintain the stability of membrane receptors including the TNF 1 (TNFR1) receptor, TLR and IL-1R (16,17). After stimulation with pro-inflammatory signals, LUBAC is recruited to attach linear Ub chains to target substrates: thus, in the event of an anomaly of one of the constituent proteins of LUBAC, this reduces its stability in the cells. Since immune responses must be regulated to avoid chronic inflammation, LUBAC activity is counter-regulated by such as OTULIN and A20. OTULIN hydrolyses the linear Ub chains, which reduces activation of the NF- $\kappa$ B and A20 pathway, can direct proteins to the proteasome (16,17). Recently, deregulation in the ubiquitin pathway has been reported in patients with auto-inflammatory diseases: abnormalities associated with defects in the linear assembly of the ubiquitin chain (LUBAC), and abnormalities associated with defects in protein deubiquitination: A20 deficiency (HA20) and otulinopenia (ORAS) (16,18–25).

Other autoinflammatory diseases are due to insufficient clearance of proteins in the immune system that are no longer needed, proteasome-related diseases, or to an accumulation of poorly-folded proteins in the endoplasmic reticulum responsible for increased secretion of pro-inflammatory cytokines; an example of such a mechanism is TRAPS syndrome (15).

Finally, some autoinflammatory diseases are linked to the inability to regulate cytokine signaling, which will lead to the development of abnormal cytokine loops that amplify and

perpetuate inflammatory responses. A good example of this mechanism is illustrated by DIRA and DITRA, in which the IL-1 and IL-36 signals of cytokine antagonists are absent (15).

In the ADA2 deficiency, there is an imbalance in the balance of pro- and anti-inflammatory macrophages in favour of pro-inflammatory macrophages, which causes inflammation of the vessel walls and the release of pro-inflammatory cytokines, including TNF (26).

In interferonopathies, some mutations induce type I interferons pathway activation leading to increased proinflammatory cytokine secretion(27).

### **3-DESCRIPTION OF THE MAIN MONOGENIC AUTO-INFLAMMATORY DISEASES (TABLE 1)**

#### **3.1. The four « historical » recurrent fevers**

Recurrent fevers are characterized by recurrent attacks of systemic inflammation manifested by sudden episodes of fever associated with elevated acute phase proteins and several clinical manifestations affecting mainly the skin and mucosae, muscles and joints, and digestive tract; the most frequent symptoms are cutaneous rashes, serositis (peritonitis, pleuritis, pericarditis), arthromyalgia and lymphadenopathy. Attacks of disease are usually separated by symptom-free intervals of varying duration, characterized by complete wellness, normal growth and normalization of inflammation biomarkers.

##### **3.1.1. Familial Mediterranean fever (FMF)**

Familial Mediterranean fever is the most frequent monogenic auto inflammatory disease, which is associated with mutations in *MEFV* gene (28–34). The main symptoms are acute inflammation attacks in serosa leading to recurrent febrile abdominal pain in most cases and the most feared complication is inflammatory amyloidosis (29).

##### ***Epidemiology***

FMF mainly affects patients originating from Mediterranean countries such as Arabic populations, Armenians, Sephardic Jews, Turks, Lebanese, Italian and Greek (29). In Sephardic Jews and Armenians, the frequency in the general population of heterozygous carriers of a mutation in *MEFV* gene is estimated from 1/4 to 1/6; and the worldwide estimated number of patients is around 100 000(29,31).

##### ***Genetics and mechanisms***

The association between *MEFV* gene and FMF was discovered in 1997; *MEFV* is a gene of average size, located in chromosome 16, comprising 10 exons, and encoding a protein named pyrin (from the Greek name of fever: pyros) (29). The disease begins in 80 to 90% of cases before the age of 20 years and has a recessive autosomal transmission; *MEFV* is expressed

only in circulating neutrophils and to a lesser degree in monocytes; the most frequent pathogenic *MEFV* mutations stand in exon 10, especially the M694V (29,31).

### ***Inflammatory attacks of FMF***

Acute attacks are characteristic of the disease, and as indicated by its name, fever is almost constant during attacks; it is rarely isolated, and frequently there are signs of acute inflammation of serosa, in decreasing order of frequency peritoneum, pleura, testicular vaginal and pericardium. Acute abdominal attack is often impressive and in the presence of a first attack, suspicion of acute appendicitis or peritonitis can lead to emergency surgery. Other organs frequently affected are joints, skin, especially in the form of a erysipelas-like erythema of the lower limbs (figure 2.A), and muscles with myalgias; most often only one organ is affected during an inflammatory attack and the peritoneum is the main target (31,33,35).

Acute attack lasts from a few hours to 72 hours, usually 2-3 days, and resolves spontaneously, sometimes leaving the patient tired for a few more days. Attacks are recurrent without any regularity and with a very variable frequency from one subject to another and from one period of life to another for a given subject. Patients have no clinical signs when they are not experiencing attacks. However, some manifestations of the disease can extend beyond the usual 72 hours, such as acute arthritis and protracted myalgias that can last several weeks. Clinical inflammation or its sequelae can have a chronic repercussion, especially joint involvement such as coxitis, much more rarely occurs chronic ascites by chronic peritoneal inflammation. Patients homozygous for the *MEFV* M694V mutation usually display a more severe clinical form. Some diseases are more frequently associated with FMF such as Ig A vasculitis, hidrosadenitis suppurativa and a special HLAB27 negative spondyloarthritis, most often axial (29). Clinical inflammatory attack is accompanied by the usual peripheral blood inflammation abnormalities: neutrophilic polynucleosis, elevation of acute phase response proteins including C reactive protein (CRP) and serum amyloid associated (SAA) (29,31).

### ***AA Amyloidosis secondary to FMF***

AA or inflammatory amyloidosis, kidney is the main organ involved; amyloid nephropathy was the leading lethal cause in patients with FMF, before the era of colchicine (36,37). Other organs preferentially affected are the digestive tract and thyroid; heart involvement is very rare in this type of amyloidosis. Genetic and/or environmental factors are involved in the development of amyloidosis in FMF. Several studies strongly suggest that amyloidosis occurs preferentially in association with homozygous *MEFV* M694V mutation. Among the candidate genes playing a role in modifying the expression of the disease are the genes encoding the SAA protein derived from the AA protein forming amyloid deposits in inflammatory



amyloidosis (=AA amyloidosis). In humans, it has been shown that some polymorphisms in *SAAI.1* variant significantly increases the risk of amyloidosis during FMF compared to other genotypes at the *SAAI* loci (31,38). Rarely some patients without clinical symptoms of the disease can be diagnosed at the stage of AA amyloidosis, which is considered as a, FMF Phenotype II, which could be explained by the existence of subclinical inflammation during FMF, as revealed by the systematic measurement of markers of inflammation between acute attacks (39).

### ***Diagnosis***

The diagnosis of FMF is based on a combination of clinical arguments and genetic diagnosis (28,29,31). There are neither specific clinical signs of FMF, nor specific marker of inflammation available in a routine diagnosis. Therefore, the diagnosis of FMF may be a diagnosis of exclusion of other diseases, depending on the clinical signs observed, which is however based on elements of certainty. Several sets of criteria have been proposed to help in the diagnosis of FMF. They are almost all based on a variable composition of the following elements: 1) presence of the most common clinical signs, 2) presence of AA amyloidosis, 3) familial character, 4) efficacy of colchicine, 5) exclusion of another well-defined disease (28,31). The discovery of the *MEFV* gene and mutations responsible for FMF provides a definite diagnostic aid, with the preliminary difficulty of defining when a DNA sequence variation becomes a pathogenic mutation. In the presence of suggestive clinical signs, the detection of 2 mutations in *MEFV* (homozygosity or composite heterozygosity) confirms the diagnosis of FMF (31). The diagnosis of FMF can also be made in subjects belonging to populations at risk and who have recent signs, with little inflammatory attack, not always fulfilling the criteria sets. Genetic analysis makes it possible to start treatment at an early stage. In the presence of at most one mutation, the diagnosis neither can be stated, nor be excluded since it is possible that not all mutations responsible for FMF are yet known. It is now established, as with other recessive diseases, that some individuals who are heterozygous for a mutation in the *MEFV* gene may have clinical signs requiring colchicine treatment. It is possible that in this case the clinical signs may diminish or even disappear in adulthood (40–42). Finally, and very rarely, in some non-Mediterranean family's certain variants of the *MEFV* gene are associated with an inflammatory dominant disease (43–46).

### ***Treatment***

There is no real treatment for acute inflammatory attack except classical analgics (29,31). The main treatment is preventive, and colchicine is efficient to prevent both attacks and AA amyloidosis development. The dosage in adults begins at 1 mg/day which is often enough to

prevent attacks, but higher doses are sometimes required, until 2.5 mg/day. Treatment with colchicine may be continued during pregnancy and lactation (47–51). Once amyloidosis is established, colchicine treatment may stabilize renal impairment, even when nephrotic syndrome exists (36,52). Rarely, patients can be resistant to colchicine, and experts have tried to definite colchicino-resistant patients. Among those patients or in case of colchicine major side effects, interleukin-1 inhibitors have recently proved their efficiency but should be prescribed after expert advice, as those expensive biologics need to be use reasonably (29,31).

### **3.1.2. Cryopyrinopathies (Cryopyrin Associated Periodic Syndrome-CAPS) or *NLRP3*-associated Auto-Inflammatory Disease (*NLRP3*-AID) in new nomenclature**

Three clinical entities previously defined independently were finally genetically grouped because there were all associated with *NLRP3* mutation: Muckle Wells syndrome, Family Cold Autoinflammatory Syndrome (FCAS) and CINCA syndrome (chronic, infantile, articular, neurological, cutaneous and articular) under the name of cryopyrinopathies or CAPS (cryopyrin associated periodic syndrome); the common feature is cold-induced urticaria (figure 2.B) (53,54). Muckle-Wells syndrome refers to the association of urticaria, predominantly renal amyloidosis and sensorineural hearing loss, transmitted in the autosomal dominant mode. Clinical inflammatory attacks include, in addition to urticaria defining the disease), signs of eye inflammation, and less often arthritis. FCAS is characterized by delayed onset (several minutes to hours) by environmental exposure to cold. Hives attacks are associated with other signs: fever, arthritis and conjunctivitis, The CINCA syndrome is a disease which is expressed from the first days of life, and which is defined essentially by a triad: cutaneous, neurological and articular. Skin signs include diffuse, non-pruritic urticarial erythema, neurological damage, chronic meningitis, and progressive joint arthropathy, especially of the knees, which can be severely deformed. This triad is associated with a characteristic facial dysmorphism (53).

Mutations of *NLRP3* have been discovered in subjects with these 3 phenotypes where the most specific clinical symptom in chronic urticaria and peripheral inflammation. Somatic mutations have been found among patients without mutation by Sanger genetic analysis, especially in CINCA syndrome (12,55); a recent review reports on 64 patients with somatic mutations and suggests that those can be found from 0.5 to 19% of patients with a clinical phenotype of cryopyrinopathy (56). Nowadays, geneticists suggest looking for *NLRP3* mutations by next generation sequencing when there is a high suspicion of cryopyrinopathy even when the disease began in adulthood (56).

The treatment is based on interleukin-1 inhibitors which have shown dramatic efficacy in patients with all 3 phenotypes, with a restriction for central nervous system involvement and deafness, especially if the delay between the beginning of symptoms and the diagnosis is long (57–60).

### **3.1.3. Intermittent hereditary TNF-1A receptor-related intermittent hereditary fever (TRAPS)**

TRAPS is a very rare disease and probably represents a large proportion of hereditary autosomal dominant transmission fevers of patients displaying abdominal pain with inflammation during more than one week among patients from all origins (61). The symptoms of inflammatory attacks are in some cases richer: fever and abdominal pain can be accompanied by myalgia, muscle stiffness, conjunctivitis, arthralgia, chest pain, testicular pain and two signs that are probably most specific to this variety of hereditary fever - periorbital edema and cutaneous rash. The most typical cutaneous signs are very painful pseudocellulitis affecting the upper as well as lower limbs, migrating from the root to the extremity of the limb during attack and which is monocyte inflammatory fasciitis. Other skin signs that are polymorphic and less typical of TRAPS exist in more than 50% of patients. AA amyloidosis can complicate the course of this chronic inflammatory disease in some families (61).

The gene responsible for TRAPS syndrome encodes for the TNF type 1A receptor. Most mutations concern the cysteins underlying the spatial structure of the extracellular part of TNFRSF1A, which reinforces the suspicion of their pathogenicity. The mechanisms of the disease are not yet fully understood. Initially described in families of Irish and Scottish origin, this disease exists in all populations (61,62). The diagnosis, based on the clinical data described above, must be confirmed by genomic DNA analysis for *TNFRSF1A* mutations (63).

Treatment with colchicine has no proven effect on preventing inflammatory attacks, nor does it appear to prevent the occurrence of amyloidosis; corticosteroids, on the other hand, have a definite effect and reduce the severity and duration of inflammatory attacks which can last several weeks and in some cases be infraclinical (60). Recently interleukin 1 inhibitors use during crisis or as attack prophylaxis has shown its efficacy; therefore, anakinra and/or canakinumab can be used in this indication (64,65).

### **3.1.4. Mevalonate kinase deficiency (MKD)**

Mevalonate kinase deficiency (MKD), formerly called Hyperimmunoglobulinemia D syndrome (HIDS) was firstly described in 1984; the presence of an original biochemical marker, the elevation of serum IgD, allowed the individualization of this hereditary autosomal recessive transmission condition (66). The clinical aspects were well described in a series of 50 patients by Drenth *et al*, essentially of Dutch and French origins and confirmed on a series of 103 and on a series of 50 described by Bader-Meunier *et al* (67,68). The disease usually begins in childhood. Inflammatory attacks typically last 7 days and can relapse every 4 to 8 weeks, with fever reaching at least 39°C, accompanied by focal signs in 2/3 to 3/4 of cases: abdominal pain, diarrhea, vomiting, arthralgia or oligoarthralgia and sometimes arthritis. Skin or mucosal manifestations are frequent and very various including erythematous macules, urticarial lesions and sometimes mouth ulcers (figure 2.C). Relatively specific compared to the 2 previous varieties of fevers, are hepatosplenomegaly and especially the presence of painful cervical adenomegalies in 94% of cases (66,69). There are no clinical signs of inflammation between attacks and the disease is very rarely complicated by AA amyloidosis (66,69). The individualization of this condition was based on the existence, both during and between attacks of a high level of serum IgD, but high level of serum immunoglobulin D is probably not highly specific and may also occur in FMF and TRAPS (70). The *MVK* gene, mutated in this disease, codes for an enzyme of the cholesterol pathway, mevalonate kinase, whose partial deficiency underlies the phenotype of MKD and the complete deficiency is the cause of a pediatric disease: mevalonic aciduria. Children with this disease also have inflammatory attacks typical with hyperimmunoglobulin D syndrome, growth retardation, dysmorphia and severe neurological disorders. The intimate mechanisms of inflammation associated with this metabolic disorder involves the interleukin-1 pathway (15,71). To date, mevalonaturia is mainly used among children and the serum IgD assay is not very specific and therefore rarely used (70).

The usual anti-inflammatory drugs, corticosteroids, colchicine, non-steroidal anti-inflammatory drugs, are generally not very active on this variety of inflammation (66). Recent studies showed the efficacy of IL-1 inhibitors, especially canakinumab with a continuous treatment (65,72,73).

### **3.2. ADA2 deficiency (DADA2) (figure 3)**

First described simultaneously by two teams in 2014, deficiency in adenosine deaminase 2 (DADA2) is a rare autoinflammatory disorder characterized by three cardinal types of manifestations: inflammatory vascular manifestations, hematologic manifestations and, to a

lesser extent, immunodeficiency (74,75). Case reports since 2014 have continuously widened the clinical spectrum of the disease, with great variation of clinical presentation even among related patients (26,76).

DADA2 is an autosomal recessive disease, whose cause has been highlighted by a whole exome sequencing genetic approach: it results from loss-of-function mutation of *ADA2* (also called *CECRI*, standing for Cat Eye syndrome Chromosome Region candidate 1). *ADA2* gene is mapped to the q arm of chromosome 22 (22q11.1) and includes 13 exons; the gene encodes the adenosine deaminase 2, a dimeric enzyme mainly expressed by myeloid cells which is involved in the purine metabolism (26,76). To date, more than 60 disease-causing mutations have been reported with poor genotype-phenotype correlation; most of them being novel mutations, only found within one single patient or family; however, most common variants seem to be more frequent in certain population: p.G47R in Georgian Jewish and Turkish individuals, p.R169Q in Dutch population and p.T360A in Italian patients (76–78).

Pathogenesis of DADA2 is still mysterious despite *ADA2*'s enzymatic activity; *ADA2* has been shown to have a substantially lower affinity for its substrate (adenosine and 2'-deoxyadenosine) than *ADA1* in physiological conditions; thereby *ADA1* rather than *ADA2* accounts for almost all of adenosine deamination and it is likely that the catalytic defect of *ADA2* is not responsible for the clinical manifestations – although patients displaying a collapsed *ADA2* activity could have a more severe phenotype (77,79). Main physiopathogenic hypothesis is a shift of the macrophage balance toward a pro-inflammatory M1 polarization rather than an anti-inflammatory M2 polarization leading to endothelial disruption (75). Indeed, *ADA2* has previously been showed to have a growth-factor activity and accounts of an *ADA2*-dependent T cell proliferation and monocyte-macrophage differentiation/proliferation which could be deficient in DADA2 patients(80). The role of type I interferon has also been hypothesized according to several observation, though not investigated yet (81–83).

DADA2 diagnosis is based on the identification of one pathogenic variant of *ADA2* at the homozygous state or two compound heterozygous pathogenic variants of *ADA2*; serum *ADA2* activity is another useful tool, which is constantly low in DADA2 patients (84).

Clinical presentation varies widely between patients, even within the same family; first symptoms usually occur during early childhood, mainly before 10 years old and 25% before one year old; however late diagnosis can be done as the oldest patient reported to date was 59 yo at the time of the diagnosis(26,76,85). DADA2 equally affects both genders worldwide (26,76). First articles on DADA2 described the inflammatory-vascular phenotype of the

disease, which is by far the most frequently reported: it consists of a vasculitis of medium- and small-sized arteries fulfilling periarthritis nodosa criteria (PreS or EULAR criteria) in one third of patients (74,75). As in most other autoinflammatory diseases, fever and inflammatory syndrome wax and wane along with vasculitis symptoms –neurological and cutaneous symptoms being the most common; ischemic strokes account for majority of neurological manifestations of DADA2 with typical MRI findings consistent with acute or chronic small-vessels ischemia of the deep brain nuclei and/or the brain stem; involvement of medium-sized vessels is less frequent: to date only one patient with intracranial aneurysm and 3 with intracranial stenosis or irregularity has been reported; transient ischemic attacks are also frequently described; hemorrhagic strokes have also been reported, although an uncertain proportion of them could be explained by antiplatelet or anticoagulant therapies given for previous ischemic strokes (26,76,78). Skin vasculopathy, present in 75% of patients, is characterized by a livedoid rash and rarely distal necrosis; in some cases – but not all – skin biopsy shows a non-granulomatous necrotizing vasculitis suggestive of cutaneous PAN and also nonspecific leukocytoclastic vasculitis and panniculitis have also been observed in others; other less frequent cutaneous/mucosal manifestations include non-specific skin rashes and mouth ulcers (76). Vasculitis can also affect other organs, such as the gastro-intestinal tract, kidney or liver (26,76,78).

Anti-TNF therapies are now the cornerstone of the treatment of the vascular phenotype of DADA2; it controls inflammatory symptoms of vasculitis and prevents strokes whereas classical immunosuppressive therapies have shown disappointing results (75,76). Of note, antiplatelet or anticoagulant therapies for ischemic strokes are considered at risk of hemorrhagic transformation and there is no consensus on their indication, unlike other causes of ischemic stroke(75,76).

DADA2 is associated with a mild immunodeficiency linked to compromised B cell compartment, resembling to common variable immunodeficiency (CVID): approximately 25% of DADA2 patients suffer from hypogammaglobulinaemia (IgM being the most affected) and 20% experience recurrent infections (86,87). Considering the humoral immunodeficiency, the most commonly infections affect the lower and upper respiratory tracts; however, herpes virus infections, consisting mainly of recurrent herpes simplex outbreaks, are also reported; though T cell compartment is normal; Thus, immunodeficiency is almost never an isolated symptom of DADA2 in a single patient (86,87). Treatment of immunodeficiency is based on intravenous immunoglobulin supplementation in case of recurrent infections (86,88). Interestingly, correction of IgM defect was reported in a few

patients treated with ant-TNF therapies (86). Finally, allogenic hematopoietic stem cells transplantation (HSCT) may be an alternative in severe cases (89).

Hematological disease is the third cardinal manifestation: mild cytopenia, especially anemia and leukopenia are frequent (26,78). Regarding severe hematological phenotypes, pure red cell aplasia is the most described and affects about 5% of patients; severe neutropenia has also been described; The only effective treatment of those severe hematological phenotypes is HSCT (76,89).

Recently a case mimicking Castleman disease has been reported and the patient was successfully treated with tocilizumab (76,90).

### **3.3.- Other monogenic AID**

#### **3.3.1. Diseases with urticaria as a main feature**

In this type of AID, systemic inflammation is dominated by a characteristic urticarial rash occasionally associated with other variable clinical manifestations. CAPS are the most emblematic AID of this group, but other pathological conditions such as NLRP12 or NLRC4 deficiency are entities with close clinical presentations. The latter condition may also be associated with severe episodes of macrophage activation syndrome.

#### ***Diseases related to NLRC4 mutations***

Recurrent fevers linked to mutations of *NLRC4* were first described in 2014 among 3 families (91–93). In two families, phenotype consisted in a neonatal association of macrophage activation syndrome and early onset inflammatory bowel disease; the third family presented with an autosomal dominant cold urticaria without hematological or digestive involvement. To date, 28 cases have since been described, 75% of which being familial with an autosomal dominant transmission, 25% being caused by de novo mutations, probably because of the severity of one particular phenotype(94–96). Two different phenotypes seem to differentiate among case reports: a first group of patients have very early onset of disease (mean 1.8 months after birth), high fever with macrophage activation syndrome (90%), severe enterocolitis (80%) and an unspecific cutaneous rash (70%) leading to very high mortality rate (40%); a second phenotype suffers from a milder disease with later onset (mean 39 months). Tropism is cutaneous with urticaria or erythematous nodes, articular frequent (arthromyalgias) and ocular (conjunctivitis or sicca syndrome). There is neither reported vital organ involvement, nor mortality nor growth retardation (94,96). Interestingly, interleukin-18 was always markedly elevated when assayed, for both phenotypes and even between attacks. Treatment is not yet codified: used for severe patients of the first phenotype, glucocorticoids,

anakinra and ciclosporin provided complete remission in only one third of cases, whereas TNF-alpha inhibitors or vedolizumab were not efficient; anti-interleukin 18 and anti-IFN gamma agents gave interesting results in life-threatening situations (92). In the second phenotype, abstention or symptomatic treatment with NSAIDs was often preferred, while two paradoxical reactions to anakinra which worsening of arthritis and induced a Crohn disease, were described out of three trials (94).

### ***Periodic fever associated with NLRP 12 mutations***

Recurrent fevers linked to mutations of *NLRP12* were first reported in 2008 in two Caribbean twins suffering from arthralgia, periodic fever and cold-induced urticaria, with spontaneous amendment of disease during adolescence (97). Since the first description, 36 cases have been reported with considerable clinical heterogeneity between authors. Regarding genetics, most cases are related to *NLRP12* polymorphisms or VUS, rendering adequate characterization of the disease even more difficult; for instance, a Chinese review of the literature with no critical analysis of case reports analyzed 29 patients considered as having a *NLRP12*-related disease (98). Only 30% of 29 patients displayed a history of elevated acute phase reactant or CRP during crises; fifty percent of cases were sporadic, and only 6 patients presented variants with undetectable frequency in the general population; the remaining 23 patients were diagnosed based on polymorphisms or variants of undetermined significance(98). The authors also included 9 patients from a *De Pieri et al.* letter who had no diagnosed *NLRP12*-associated periodic fever (99). Meanwhile, a Russian team screened *NLRP12* variants in 246 children suffering from periodic fevers with 86% of common variable immunodeficiency diagnostic: 15 patients with *NLRP12* variants were retained as having an autoinflammatory disease linked to *NLRP12*; they presented a very low frequency of urticaria, arthralgia and cold sensitivity, respectively 13%, 20% and 20%, but 60% of recurrent infections (100). Recurrent infections in *NLRP12* related disease are only reported by this author: out of the 18 identified *NLRP12* variants in this article, twelve had a detectable frequency in the general population (99). Considering all 36 declared cases in the literature, there is neither report of organ failure, nor amyloidosis nor disease-related mortality; altogether, the actual published data seems both insufficient in quantity and quality to currently affirm with certainty that *NLRP12* mutations can produce genuine autoinflammatory syndromes (97–100).

### **3.3.2. Diseases with recurrent fever as a main feature**

#### ***Recurrent fever associated with TNFRSF11A mutations.***



A French team reported three patients with hereditary recurrent fever and a mutation of the *TNFRSF11A* gene, a gene known to regulate fever in rodents (101). This mutation was associated with increased secretion of several inflammatory cytokines and altered the biological effects of the receptor on NF- $\kappa$ B signalling. This entity was clinically very close to TRAPS syndrome, with prolonged fevers, and is associated with mutations in a gene of the same family, *TNFRSF11A* (101).

***Recurrent fever and polyarthritis with LACCI/FAMIN mutations.***

A mutation of the *LACCI/FAMIN* gene has been found to date among 15 patients, all from consanguineous marriages with systemic forms of idiopathic juvenile arthritis from Saudi Arabia (n=13) or Lebanon (n=2); the transmission was autosomal recessive (102,103). This gene encodes the laccase enzyme, which belongs to the multi-brass oxidase family that contains other enzymes such as ceruleoplasmin. All patients displayed symmetrical polyarthritis in both small and large joints with fever and inflammatory syndrome beginning between 12 and 36 months of life. Other clinical signs included maculopapular rash (n=13), organomegaly (n=7), deep adenomegalies (n=2); any patients developed macrophage activation syndrome (102,103).

**3.3.3. Diseases with sterile skin /joint / bone inflammation as a main feature**

Other autoinflammatory diseases are dominated by sterile inflammation of joints, bones and skin. This category contains many different rare diseases. The most frequent are those associated with *NOD2/CARD15* mutations, of which nearly 150 mutations are described to date.

***Diseases associated with NOD2 mutations***

Blau syndrome: this is a dominant autosomal disease linked to function gain mutations of *CARD15/NOD2* gene, which most typical presentation is a triad with joint, cutaneous and ocular involvement (104). It is named “Blau syndrome” in familial forms and early onset sarcoidosis in sporadic forms. Regarding rheumatological lesions, more than 90% of patients have symmetrical polyarthritis with synovitis and tenosynovitis, mainly affecting the extremities: hands with an involvement of proximal interphalangeal joints, which can lead to camptodactily, wrists, ankles and knees. Cutaneous lesions consist of a maculo-micro-papular erythematous and eczema-like rash, beginning in the first year of life, which may mimic atopy or vulgar ichthyosis; a skin biopsy will show granuloma without necrosis. Ophthalmological involvement is responsible for granulomatous uveitis very serious in 80% of patients. Other

rarer injuries include: a knotty rash, cranial nerve damage (104). Interestingly, a case of Blau syndrome with a somatic mutation gain of NOD2 function has recently been published (14). Other NAID disease, for *NOD2*-associated autoinflammatory diseases: in 2011, Yao et al described a new category of auto inflammatory disease called NAID for *NOD2*-associated autoinflammatory disease (or more recently Yao syndrome) which is associated with variants of *NOD2* IV58+158 or R702W (105–107). It is a sporadic entity affecting Caucasians with a feminine predominance (70%) and diagnosed at a mean age of 35 years old; Patients display recurrent episodes featuring erythematous or macular plaques of the trunk in most cases, non-erosive oligo or polyarthritis in almost 80% of cases with fairly characteristic swelling of the distal extremities, gastrointestinal symptoms such as abdominal pain and diarrhea, and recurrent fever with general symptoms such as fatigue and weight loss; sometimes serositis are noted (105,106). However, it is important to remain cautious about this entity, which merely associates sporadic cases of non-specific phenotypes with genetic variants of undetermined significance to date.

#### ***Diseases associated with PSTPIP1 mutations***

Diseases related to *PSTPIP1* mutations are called PAID for *PSTPIP1*-associated autoinflammatory diseases (6,108) . To date, more than 27 different mutations have been described in the *PSTPIP1* gene, which encodes a protein called CD2-BP1 (CD2-binding protein 1), an adaptive protein that can bind to inflammasome pyrin; this protein is involved in the organization of cytoskeletal structures and has an impact on the cellular dynamics of innate immunity cells, the release of IL-1 and modulation of T cells activation (6). Patients experience recurrent inflammatory attacks with systemic signs such as fever, inflammatory skin and joint lesions; In fact, as in cryopyrinopathies, it is a spectrum of diseases, the most frequent and firstly described was PAPA (Pyogenic Arthritis, Pyoderma gangrenosum and Acne syndrome). Since then, several different clinical entities associated with different mutations of this gene have been identified, the most serious being PAMI syndrome (PSTPiP1-Associated Myeloid-related-protein. In PAMI, there is an increase in the synthesis of a pro-inflammatory alarmin: MRP8/14 (myeloid-related-protein) protein, also known as calprotectin or S100A8/A9 protein which seems interesting to measure in peripheral blood of patients with PAID-compatible clinical phenotype in order to guide the sequencing of *PSTPiP1* when high (6).

PAPA syndrome (Pyogenic Arthritis, Pyoderma gangrenosum and Acne syndrome). This syndrome is the most common disease associated with *PSTPiP1* mutations and combines

recurrent arthritis with neutrophilic disease in more than 75% of cases and cutaneous lesions: severe cystic acne in more than 50% of cases, pyoderma gangrenosum in 33% of cases, mouth ulcers, aseptic abscesses, aseptic pustules, sometimes psoriasis or even suppurated hidradenitis (109).

PAMI syndrome (*PSTPIP1*-Associated Myeloid-related-proteinemia Inflammatory syndrome. It is clinically associated with aseptic arthritis in more than 55% of cases, pyoderma gangrenosum in almost half of cases, ulcerated and/or necrotic lesions in 30% of cases, acne and/or pustular rash in 20-25% of cases (6). Signs specific to this entity include hepatosplenomegaly in almost 90% of cases, polyadenopathy in 40% of cases and pancytopenia (almost constant neutropenia, very frequent anemia, thrombocytopenia in half of the cases) (6,108). Nephropathy may occur with renal impairment in 20%; growth retardation or mental retardation. Rarely cerebral vasculitis may develop (6). Biologically, the main characteristics, almost 90% of cases, are an extremely high serum calprotectin level (MRP8/14) and hyperzincemia, both being a much simpler and faster way to diagnose PAMI syndrome than genetics (6,108). These patients have a good response to anti-interleukin-1 biologics such as anakinra.

PAPASH syndrome (Pyoderma gangrenosum, Acne and Hidradenitis Suppurativa) was given for the combination of aseptic arthritis, pyoderma gangrenosum, acne and suppurated hidradenitis. This entity is close to features encountered among patients with nicastrin mutations (*NCSTN*) and/or mutations in *MEFV* exon 2 (see *infra*) (110).

PAPA-like syndrome (Pyogenic Arthritis, Pyoderma gangrenosum and Acne-like syndrome) combines arthralgia of acne and pyoderma gangrenosum, mouth ulcers and anemia (111).

PAC syndrome (Pyoderma gangrenosum, Acne and ulcerative Colitis) combines ulcerated colitis and severe acne, recurrent skin ulcerations, severe pustular rash with sometimes pyoderma gangrenosum (112).

***Auto-inflammatory syndrome with neutrophilic dermatosis associated with MEFV exon 2 mutations (PAAND=periodic auto-inflammation with neutrophilic dermatosis).***

It is a dominant autosomal syndrome discovered initially in 2016 in a large Belgian family with recurrent episodes of fever with arthromyalgia and neutrophilic dermatosis beginning early in life (4). Mutations *MEFV* in the p.S242R position (exon 2) have been found in a different domain from the classical FMF mutations. It was then confirmed in two other patients, one French and one Lebanese (4). A very recent publication has demonstrated *MEFV* mutation in exon 2, codon p.E244S, in a family of Spanish origin with three affected members

(5). They had pustular acne, suppurative hidradenitis, pyoderma gangrenosum and neutrophilic panniculitis. These two publications show that the spectrum of diseases linked to *MEFV* mutations is not limited to the classic familial Mediterranean fever of recessive transmission since, in the case of exon 2 mutation, patients of non-Mediterranean origin have a dominant transmitted disease with neutrophilic dermatoses in the foreground and may even mimic suppurative hidradenitis (4,5,27).

***Majeed's Syndrome (LPIN2 mutations)***

It is an autosomal recessive disease, described in a few predominantly Bedouin families, which combines recurrent multifocal chronic osteomyelitis, recurring fevers every 2 to 4 weeks lasting during 3 to 4 days or more, neutrophilic dermatosis, especially Sweet's syndrome or aseptic skin pustulosis or even psoriasis and congenital anemia. Most often the diagnosis is made in childhood with associated growth retardation, but a few cases have been described in adolescents/young adults. Mutations of the *LPIN2* gene have been reported in these patients (113,114).

***DIRA: Inflammatory disease associated with mutations of the IL-1 receptor antagonist or DIRA (deficiency of the interleukin one receptor antagonist).***

Recessive mutations of the IL-1 receptor antagonist have been found in some children with highly inflammatory neonatal disease associated with pustules resembling pustular psoriasis, multifocal aseptic osteomyelitis with periostitis. Patients display no or mild fever but have significant elevation of the biological markers of inflammation. The disease is autosomal recessive and highly susceptible to anakinra inhibition of interleukin-1(115) .

***DITRA: Inflammatory disease associated with mutations of the IL-36 receptor antagonist or DITRA (deficiency of the interleukin thirty-six receptor antagonist).***

It is an autosomal recessive disease described in 2011 in Tunisian families. Patients with generalized pustular psoriasis who started mostly in childhood. All of them had a diffuse erythematous, squamous, rapidly erythematous rash, progressing with relapses and accompanied by high fever associated with an inflammatory syndrome. These patients are at risk of sepsis and anakinra has been partially effective in some patients (116). More recently ustekinumab may have a complete efficacy on general signs and skin rash (117).

***NAIAD: Auto inflammatory syndrome with arthritis and dyskeratosis associated with NLRP1 mutations (NAIAD).***

This new entity described in 2017 in 2 families is autosomal recessive or dominant according to mutations (118). The onset is early in life, during the first six months: clinical presentation is rich with polymorphic mucosal and skin damage such as papillary or filiform hyperkeratosis, pseudo-phrynoderma, HPV negative condylomas, extended candidiasis; polyarthritis predominant in the knees, ankles, wrists and hands, with abnormalities in bone growth, and unexplained recurrent fever often associated with dysimmunity. NLRP1 inflammasome activating mutations are responsible for interleukin-1 hypersecretion and a decrease in CD27+ memory B cells, and anti-TNF or anti-IL-1 therapy has been shown to be effective(118). Other mutations of *NLRP1* have been described with a different clinical phenotype (15).

***CAMPS: Pityriasis rubra pilaris syndrome associated with CARD14 mutations***

This dominant autosomal disease has recently been described in families with pityriasis rubra pilaris (119,120). The disease begins before the age of 3 years and is characterized by extensive erythematous and sometimes scaly coalescent extensive plaques containing islets of healthy skin associated with follicular papules and palmoplantar keratoderma but without psoriasis-like lesions (119,120). The mutations of the *CARD14* gene encode a protein mainly expressed on keratinocytes and capable of activating the NF-KB pathway. Histologically, there is a parakeratosis, or orthokeratosis, acanthosis and mononucleated dermal infiltrate (119).

***Hidradenitis suppurativa associated with nicastrin mutations (NCSTN)***

In 2011 Liu described cases of suppurativa hidradenitis associated with mutations of the *NCSTN* gene (121). Nicastrin is a transmembrane protease type glycoprotein acting as a gamma-secretase (121). Since then, several teams have reported families with a dominant autosomal transmission of suppurativa hidradenitis in several countries such as China, France and Iran (122–124). Depending on the families affected presenting with only recurrent aseptic abscesses of the large folds (axillar, inguinal, perineal, and anorectal) or associated with pyoderma gangrenosum and acne; this disease is therefore a differential diagnosis of diseases associated with *PSTPIP1* mutations (PAID) and *MEFV* exon-2 mutations (PAAND) (4,5,124,125).

### 3.3.4. Ubiquitinopathies

In addition to the well-known autoinflammatory interleukin1 (IL-1) and interferon pathways, the range of possibilities widens with the description of negative regulation defects of the NF- $\kappa$ B pathway. The NF- $\kappa$ B pathway initiated upon contact of a ligand with tumor necrosis factor receptor 1 (TNFR1) plays a critical role in the initiation of the inflammatory process since it produces major cytokines such as IL-1, interleukin 6 and TNF; its downregulation is essential for stopping the inflammatory process and depends on the level of ubiquitination of TNFR1-associated proteins and other intermediate compounds. A20 and OTULIN are proteins that modify ubiquitination and their defect can induce the NF- $\kappa$ B pathway activation with excessive production of proinflammatory cytokines (16,126).

#### ***HA20 haploinsufficiency (table 2).***

The initial description by Zhou *et al*, reported 16 patients with HA20 and clinical features more detailed in a recent publication by the same team (18,19). The patients come from 7 families including 5/7 multiplexes with a dominant transmission. In these initial patients, the disease began early in life with some similarities with Behçet's disease due to the presence of bipolar aphthae in most patients as well as ocular inflammation (19). It was distinguished by the presence of febrile attacks in most cases and always associated with biological inflammation during attacks which are not usual in Behçet's disease with systemic inflammation observed only during attacks of serositis, vasculitis and digestive involvement and rare in Asian populations. Fifty-one patients have yet been reported in the literature within 3 years, mostly women (60%), and more frequently from Japan (60% of all cases) but the disease can affect worldwide. The main features are the dominant autosomal transmission, the early age at onset, in the first year of life, and the oral aphtae lesions in 88% of cases even though genital aphtae ulcers can also occur in 68% of cases. Recurrent fever and digestive symptoms, such as bloody diarrhea are frequent during attacks. Cutaneous lesions are various (45%) and arthromyalgia observed in 1/3 patients. One third of patients displayed autoantibodies especially antinuclear and thyroid-specific antibodies (16,19,127).

All patients described required treatments ranging from colchicine alone (effective in 8 patients) to combinations of corticosteroids and immunosuppressants (methotrexate, azathioprine, thalidomide, cyclophosphamide, tofacitinib). Overall corticosteroids were effective but with high levels of corticosteroid dependence responsible for major side effects. The biotherapies used were anakinra, tocilizumab, and anti-TNF and were considered to influence systemic inflammation. Intravenous immunoglobulin replacement therapies have

been used in the few patients with associated humoral immune deficiency; in patients with HA20 a personalized therapeutic approach should rely in part on detected cytokine levels since there is probably a large phenotypic variability which complicates the establishment of standardized management (18,126,127).

***ORAS: otulinopenia or ORAS (OTULIN-related autoinflammatory syndrome) by mutations of OTULIN.***

A new recurrent hereditary fever has been discovered in connection with mutations of a gene called *OTULIN* that encodes a deubiquitinase (20,25). Two teams reported a total of four mutations of this gene in eight patients from four consanguineous families of different origins (English, Turkish and Pakistani). It is an autosomal recessive transmission disease characterized by severe neonatal systemic inflammatory manifestations consisting of prolonged fevers, joint swelling, severe diarrhea with growth delay. The attacks are long and do not resolve without treatment (20,25). On the skin level, various rashes have been described including erythema, pustules, subcutaneous nodules, panniculitis and lipodystrophy. Fever usually lasts for about two weeks. Serum total immunoglobulin levels is discreetly elevated and sometimes there are anti-smooth muscle antibodies. Five of 6 patients with ORAS reported in the literature were treated initially with anti-TNF drugs; with the last one received corticosteroids and anakinra (20,25,126,128).

**3.4. Interferonopathies**

It is a heterogeneous group of diseases characterized by increased expression of interferons (IFN) type 1 that can lead to the secretion of proinflammatory cytokines by innate immune cells. These diseases are mainly diagnosed in paediatrics and have phenotypic similarities and skin signs of chilblain lupus or livedo present in the first few months of life and neurological manifestations (from asymptomatic cerebral calcifications to encephalopathies) (129,130).

A disease called SAVI, known as STING-associated vasculopathy with onset in infancy, belonging to interferonopathies, has been described in patients with severe skin vasculopathy with possible ulcers and interstitial lung disease which can progress to early pulmonary fibrosis and systemic inflammation; This dominant autosomal disease is associated with gain-of-function gain mutations of *TMEM173* encoding a protein called STING (130–132). Lung damage is severe and is the main cause of death and may require lung transplantation (130).

**3.5. MAI with immune deficiency**

### **3.5.1. Deficits in *HOIL1* and *HOIP***

Mutations of *HOIL-1* (or *RBCK1*), a subunit of the LUBAC complex which ubiquitins intracytoplasmic proteins before addressing them to the proteasome, have been described by a French team. This syndrome associates recurrent fever, inflammatory colitis, hepatosplenomegaly, adenomegalies, recurrent pyogenic infections and severe B immune deficiency (decrease in switched B lymphocytes), but no autoimmunity. There is cardiac amylopectinosis (23).

Mutations of *HOIP* (or *RNF31*), another subunit of the LUBAC complex which ubiquitinates intracytoplasmic proteins before addressing them to the proteasome, have been described by the same French team; this syndrome combines a recurrent fever with arthralgia, diarrhea, splenomegaly, subclinical amylopectinosis and lymphangiectasis, no autoimmunity, hypogammaglobulinemia and T-cell abnormalities (133).

### **3.5.2. Diseases associated with *PLCG2* mutations (PLAID and APLAID)**

Two dominant autosomal diseases associated with different mutations of the same gene, *PLCGamma2*, are responsible for autoinflammation associated with immune deficiency and immune deregulation: PLAID and APLAID.

The PLAID ("*PLCG2*-associated Antibody-deficiency and Immune Dysregulation") was described in 27 patients from three American families in 2012: all had environmental cold urticaria with a positive ice cube sign (100%), an immune deficiency close to a common variable immunodeficiency (CVID) with recurrent ENT and pulmonary infections (75%), the presence of anti-nuclear antibodies or autoimmune disease including thyroid disease in 56%; seven patients had granulomas on skin biopsy examination (134). This disease is on the verge of autoinflammation (low level) and dysimmunity (low level).

APLAID (false sense mutations with function gain), initially described in a family, is therefore rarer. It means "Autoinflammatory *PLCG2*-associated Antibody-deficiency and Immune Dysregulation". It combines the presence of bullous and/or oozing skin lesions (without cold urticaria), enterocolitis, ocular inflammation (ulceration/erosion, which can lead to intraocular hypertension and cataracts), non-specific interstitial lung disease, arthralgia and moderate immunodeficiency with recurrent sino-pulmonary infections due to low serum levels of IgM and IgA. These PLCgamma abnormalities modify the intracellular metabolism of calcium, activating the inflammasome NLRP3(135).



### **3.5.3. PFIT for periodic fever with immunodeficiency and thrombocytopenia (*WDR1* mutation).**

It is an autosomal recessive disease described for the first time in 2017 in Pakistani twins from inbreeding parents (136). From birth, it combines recurrent fever, mouth ulcers and perianal canker sores, severe opportunistic infections with encapsulated bacterium or fungus and thrombocytopenia with small-sized platelets (136). The disease is linked to mutations in the *WDR1* gene, whose loss of function leads to the accumulation of actin molecules that activate pyrin, responsible for interleukin-18 hypersecretion. Disturbance of the cytoskeleton leads to dysfunction of T cells, antigen-presenting cells and megakaryocytes, such as in Wiskott-Aldrich syndrome (136). The only effective therapy to date appears to be bone marrow allografting, corticosteroids and biotherapies being only partially effective and increasing the risk for infection (136).

### **3.5.4. *TRNT1* mutations in SIFD syndrome**

Mutations of the *TRNT1* gene associated with a syndrome associating: immune-deficit sideroblastic anemia, recurrent fever and delayed development (SIFD for Sideroblastic anemia with B-cell Immunodeficiency, periodic Fevers and Developmental delay, *TRNT1* mutations) (137). The cases mainly concern young children of all ethnic origins who present with severe (microcytic) anemia (7g/dL), recurrent fever, attacks of major digestive symptoms such as diarrhea, various neurological signs (epilepsy, deafness, mental retardation), as well as nephrocalcinosis and panhypogammaglobulinemia, with absence of total B lymphocytes. Only one adult has been reported to date due to high morbidity/mortality rates. The *TRNT1* gene encodes an RNA polymerase necessary for cytosolic maturation and transfer of RNA to mitochondria (137,138).

### **3.5.5 Other rare AID with immunodeficiency**

ADA2 deficiency is frequently associated with hypogammaglobulinemia and is described above in section 3.4 (26,76). More recently patients with *TNFAIP3* mutation (described in section 3.2.4.1) and *NOD2* variations (described in section 3.2.3.1) have been reported with immune deficiency (18,128,139).

Mutations in *NFKB1* and *NFKB2* were associated in some cases with autoinflammatory features and primary immunodeficiencies which could mimic Behçet's disease or common variable immunodeficiency with or without alopecia and viral infections such as EBV infection (140,141).

### **3.6. H syndrome**

H syndrome is an autosomal recessive genodermatosis firstly described by Molho-Pessach *et al* in 2008 (142). It is associated with mutations in *SLC29A3* gene which encodes the human equilibrative nucleoside transporter 3 (hENT3) (143). The name of H syndrome was chosen to represent the most frequent features: cutaneous Hyperpigmentation and Hypertrichosis, Hepatosplenomegaly, Hearing loss, Heart anomalies, Hypogonadism, low Height, Hyperglycemia/insulin dependant diabetes mellitus and Hallux valgus/flexion contractures. Cutaneous hyperpigmentation and progressive sclerodermatous induration, typically affecting the medial thighs are pathognomonic. Other systemic features are reported as well as, exophthalmos or eyelid swelling, lymphadenopathy, gastro intestinal symptoms such as chronic diarrhea, pancreatic dysfunction, skeletal abnormalities(142,144). Histological examination of skin lesions or lymphadenopathy shows marked fibrosis and infiltration by small histiocytes expressing CD68; perivascular infiltrates composed of lymphocytes, plasma cells, and mast cells accompanied by hemosiderin deposition [24]. It can mimic Rosai-Dorfman disease with CD60+ S100+ CD1a- histiocytes infiltration and emperipolesis (145,146). It belongs to the R group of the revised classification of histiocytoses and related neoplasms by the Histiocyte Society [26]. Chronic inflammation is a classic biological feature and some patients display recurrent fever. It can be severe and often refractory to conventional immunosuppressive drugs or blockade of interleukin-1 and tumor necrosis- $\alpha$  and a few reports suggesting efficacy of tocilizumab have been published (147,148).

### **4-NON-MONOGENIC AID.**

Non-monogenic AID can be called "unclassified" MAI when they do not meet the criteria for the diseases mentioned above but have the general clinical-biological criteria for autoinflammatory diseases. These diseases are characterized by episodes of recurrent fever with biological inflammatory syndrome and clinical features of the auto-inflammatory type, without any genetic cause being identified to date. Some non-Mendelian inflammatory diseases have clinical, histological, pathophysiological or genetic similarities with inherited autoinflammatory syndromes, but appear to have a multifactorial origin.

#### **4.1. Schnitzler's syndrome**

Schnitzler's syndrome, defined by the association of adult acquired urticaria and monoclonal IgG or IgM by L. Schnitzler in 1972, shares with cryopyrinopathies a clinically and

histologically very similar rash (neutrophilic urticaria) (149). A Dutch team reported the presence of NLRP3 somatic mutations restricted to the myeloid line in patients with Schnitzler's syndrome but they were not confirmed in a larger population (150,151).

#### **4.2. The systemic form of juvenile idiopathic arthritis and Still's disease in adults**

The systemic form of juvenile idiopathic arthritis (FS-AJI) is classified as an idiopathic juvenile arthritis but is a auto-inflammatory disease (152). According to the International League of Rheumatology Associations classification, the definition of FS-IAJI is a fever of at least two weeks duration preceding or accompanying arthritis of unknown origin, of at least six weeks duration, which begins before the age of 16 years; accompanied by at least one of the following signs: fugitive rash (figure 2.D), adenopathy, hepatomegaly and/or splenomegaly, serositis. The exact etiology of FS-AJI is currently imperfectly known but is characterized by a deregulation of innate immunity.

Adult onset Still's disease is undoubtedly a heterogeneous entity characterized by the association of 4 clinical-biological cardinal elements: marked fever, evanescent skin rash, arthralgia or arthritis, and neutrophilic polynuclear hyperleukocytosis in the absence of rheumatoid factor or antinuclear antibodies (153). Thus defined, Still's disease was an autoinflammatory disease before the hour, although the molecular and cellular mechanisms underlying it have not yet been fully elucidated.

The management of these two entities aims to obtain the remission of systemic and articular manifestations and prevent complications such as joint destruction, inflammatory amyloidosis. Treatment is based on non-steroidal anti-inflammatory drugs (NSAIDs) in mild and in severe forms corticosteroids, methotrexate and anti-IL1 and anti-IL6 biotherapies, especially in cases of joint damage (154).

#### **4.3. Aseptic abscess syndrome**

It is defined by the existence of diffuse tissue abscesses with neutrophils, predominantly in intra-abdominal organs, and more rarely extra-abdominal (lung, brain, skin); it may be associated with Crohn's disease or relapsing polychondritis, or even with pyoderma gangrenosum, or be isolated; there is sometimes identical personal or familial history (155,156).

#### **4.4. PFAPA syndrome**

PFAPA syndrome is the leading cause of recurrent fever in pediatrics; the acronym PFAPA stands for "periodic fever aphthous stomatitis pharyngitis adenitis" (157). This syndrome combines recurrent fever of very regular frequency about once a month with pharyngitis,

mouth ulcers (figure 2.C), cervical adenopathy, sometimes headache, and abdominal pain for 3 to 6 days. Single-dose steroids are very effective. The prognosis is good: usually clinical signs disappear in adolescence, but adult cases have already been described (157,158).

### **5-DIAGNOSTIC CHECK-LIST FOR AID (TABLE 3)**

Table 3 proposes a plan to guide the clinician suspecting an AID. Some specific features suggesting one or another AID are indicated in the third column. The plan of an AID's semiological analysis to orientate itself towards this or that category and guide a possible genetic analysis.

#### **5.1. Family history**

Draw the family tree and collect the country or region of origin of his grandparents. The objectives are to look for Mediterranean area origin and see if each generation is affected, suggesting dominant autosomal transmission or, on the contrary, horizontal transmission suggesting recessive heredity; just like inbreeding unions orientating towards a recessive trait. Cases of death due to kidney failure (dialysis patients) as well as other inflammatory diseases possibly more frequent in families with AID (inflammatory disease of the digestive tract, psoriasis, spondylitis etc.) will also be investigated.

#### **5.2. Personal history**

Ask for the age at onset (beginning of symptoms) and the duration of attacks in days : The age at which the first symptoms began is very important to evoke a Mendelian AID. For example, in the most severe phenotypes of cryopyrinopathies, urticaria is often present in the first few days of life; in the case of mevalonate kinase deficiency, febrile seizures and digestive disorders often begin in the first year of life. More likely to be referred to as Somatic Mutagenic AID if symptoms are atypical (mitigated) or begin after age 40 yo. Similarly, the duration of relapses is interesting to collect: when the crisis lasts more than 7 days, one thinks more of a TRAPS syndrome (or more rarely of the deficiency in mevalonate kinase), than of a familial Mediterranean fever (figure 4).

#### **5.3. Clinical symptoms in crisis (figure 5 and table 1).**

Recurrent fevers are usually accompanied by stereotyped clinical signs, with the three systems most commonly involved being the cutaneous/mucosal, digestive tract and musculoskeletal systems. Table 1 summarizes the main outcomes that need to be addressed as a matter of priority for an AID.

### **Cutaneous features (figure 2)**

The most suggestive skin lesions are urticaria, mouth ulcers and or bipolar aphthae, erythema, pustules, livedo, lipodystrophy of the face or limbs, frostbite, livedo, purpura. Any suspicious lesion must be biopsied in search of a specific histological lesion (neutrophilic infiltrate, vasculitis, granulomas...). The patients should if possible take pictures of their lesions when attacks occur at home and send them to their physician by email or cellular phones or present them during the consultation.

### **Articular**

The interrogation looks for myalgia, arthralgia and will specify their location. The clinical examination will look for arthritis, synovitis and arguments for sacroiliitis, spondyloarthritis.

The main serous membrane localizations are the peritoneum responsible for abdominal pain, the pleura, responsible for chest pain and less frequently the pericardium, synovial and the tunica vaginalis.

### **Digestive tract**

Apart from abdominal pain of aseptic peritonitis, cramp-like pain can be secondary to deep adenomegalies; diarrhea is sometimes found at the end of the FMF crisis but is above all reminiscent of inflammatory colitis (MKD, or other AID with MICI). In case of surgery, the surgical report must be retrieved.

### **Neurological**

Interrogation and clinical examination look for headache, chronic aseptic meningitis, stroke, paraparesis

### **Ophthalmic**

Interrogation and clinical examination look for uveitis, conjunctivitis, scleritis, episcleritis, glaucoma.

### **ORL**

Interrogation and clinical examination look for sensorineural deafness, chondrite, cervical adenomegalies

### **Immuno/hematological**

Interrogation and clinical examination look for hepatosplenomegaly, peripheral adenomegalies, repeated bacterial infections or opportunistic infections suggesting immune deficiency, signs consistent with cytopenia (pallor, purpura)

## **5.4. Blood test to detect inflammatory markers in crisis**

The presence of an acute phase response in crisis must be objectively assessed by measuring CRP, search for a hyperleukocytosis with a predominance of neutrophilic polynuclears in the bloodstream and sometimes erythrocyte sedimentation rate in children. The patient should be given a blood test prescription for attacks, and three evidence of CRP elevation (three different attacks) for at least 6 months must be gathered to consider AID as possible. In addition, it is also interesting to have the result of CRP level during the non-crisis time to check their normal rate. Except in interferonopathies, CRP levels are always elevated in crisis of AID.

### **5.5. Check for diagnostic criteria**

Some diseases are defined by diagnostic criteria such as FMF, diseases associated with NOD2 or NAID mutations, Schnitzler's syndrome, Still's disease and cryopyrinopathies [14-19]. For the 4 historical recurrent fevers (FMF, TRAPS, CAPS, MKD, there is a website which allows the clinician to be directed towards one of the 4 diseases with an online algorithm (link: <http://printo.it/eurofeer/scoreCriteria.asp>) developed by the pediatrician's from Eurofever working group (63). It can be useful in daily practice to guide a request for targeted DNA analysis.

## **6-MAIN TREATMENT STRATEGIES**

Daily colchicine remains the reference and preventive treatment for FMF attacks. Compliance must be verified in the event of inefficiency. For CAPS, anti-IL-1 is the reference treatment and provides a complete control of inflammatory manifestations in more than 90% of cases. In other rare monogenic AIDs dependent on interleukin-1, treatment is not always codified. Overall in inflammasomopathies, anti-IL-1 drugs are tempted first, then if ineffective, should be discussed anti-IL-6 or anti-TNF drugs, the latter being very effective in ADA2 deficiency (76). In ubiquitinopathies, anti-IL-1 agents have been used, sometimes successfully and in the event of failure of anti-TNF agents. About the rare diseases combining immunodeficiency and autoinflammation, their treatment is not codified, it is necessary to act in priority on the most clinically severe auto inflammatory symptoms by a biotherapy and to discuss a supplementation by polyvalent immunoglobulin on the other hand, or even bone marrow allograft in some very severe cases. In general, the treatment of these very rare diseases must be discussed/decided in a multidisciplinary consultation meeting with experts who are used to treat these patients.

## 7-CONCLUSIONS

Analysis clinical signs during relapses is very important for the precise diagnosis of an auto-inflammatory disease (AID). More and more effective treatments for inflammatory manifestations are available to relieve patients and prevent the development of secondary amyloidosis (AA amyloidosis), the chronic complication of these inflammatory diseases. Since the discovery of the familial Mediterranean fever gene 20 years ago, great progress has been made in genetics to better dismember these rare diseases of innate immunity. Interestingly, the same gene may be responsible for a varied spectrum of more or less severe clinical phenotypes such as cryopyrinopathies and diseases associated with *MEFV* mutations; and for some newly discovered diseases, the phenotypic spectrum is certainly not yet completely known: such as the *ADA2* deficiency. Indeed, in that disease, initially described in 2014, other features were recently reported with patients displaying immunodeficiency or even erythroblastopenia or a Castleman-like disease (76,90)! Thus, this is a new field of systemic diseases in adult and pediatric internal medicine, which will lead to interesting opportunities in clinical, pathophysiological and genetic discoveries for the next coming years.

### Conflicts of interest:

The authors state that they have no conflict of interest in relation to this manuscript. The following authors declare that they have received occasional fees as consultants or assistance in attending congresses of Novartis and SOBI laboratories: SGL, GG.

## References

1. Grateau G, Hentgen V, Stojanovic KS, Jéru I, Amselem S, Steichen O. How should we approach classification of autoinflammatory diseases? *Nat Rev Rheumatol*. 2013 Oct;9(10):624–9.
2. Ben-Chetrit E, Gattorno M, Gul A, Kastner DL, Lachmann HJ, Touitou I, et al. Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study. *Ann Rheum Dis*. 2018 Aug 12;
3. Manthiram K, Zhou Q, Aksentijevich I, Kastner DL. The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. *Nat Immunol*. 2017 Jul 19;18(8):832–42.
4. Masters SL, Lagou V, Jéru I, Baker PJ, Van Eyck L, Parry DA, et al. Familial autoinflammation with neutrophilic dermatosis reveals a regulatory mechanism of pyrin activation. *Sci Transl Med*. 2016 Mar 30;8(332):332ra45.
5. Moghaddas F, Llamas R, De Nardo D, Martinez-Banaclocha H, Martinez-Garcia JJ, Mesa-Del-Castillo P, et al. A novel Pyrin-Associated Autoinflammation with Neutrophilic Dermatitis mutation further defines 14-3-3 binding of pyrin and distinction to Familial Mediterranean Fever. *Ann Rheum Dis*. 2017 Aug 23;
6. Holzinger D, Roth J. Alarming consequences - autoinflammatory disease spectrum due to mutations in proline-serine-threonine phosphatase-interacting protein 1. *Curr Opin Rheumatol*. 2016 Sep;28(5):550–9.
7. Romberg N, Vogel TP, Canna SW. NLRC4 inflammasomopathies. *Curr Opin Allergy Clin Immunol*. 2017 Sep 27;
8. Caso F, Galozzi P, Costa L, Sfriso P, Cantarini L, Punzi L. Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease. *RMD Open*. 2015;1(1):e000097.
9. Sarrabay G, Grandemange S, Touitou I. Diagnosis of cryopyrin-associated periodic syndrome: challenges, recommendations and emerging concepts. *Expert Rev Clin Immunol*. 2015;11(7):827–35.
10. Omoyinmi E, Standing A, Keylock A, Price-Kuehne F, Melo Gomes S, Rowczenio D, et al. Clinical impact of a targeted next-generation sequencing gene panel for autoinflammation and vasculitis. *PLoS ONE*. 2017;12(7):e0181874.
11. Rowczenio DM, Trojer H, Omoyinmi E, Aróstegui JI, Arakelov G, Mensa-Vilaro A, et al. Brief Report: Association of Tumor Necrosis Factor Receptor-Associated Periodic



- Syndrome With Gonosomal Mosaicism of a Novel 24-Nucleotide TNFRSF1A Deletion. *Arthritis & Rheumatology* (Hoboken, NJ). 2016 Aug;68(8):2044–9.
12. Mensa-Vilaro A, Teresa Bosque M, Magri G, Honda Y, Martínez-Banaclocha H, Casorran-Berges M, et al. Late onset cryopyrin-associated periodic syndrome due to myeloid-restricted somatic NLRP3 mosaicism. *Arthritis & Rheumatology* (Hoboken, NJ). 2016 Jun 6;
  13. Mensa-Vilaro A, Cham WT, Tang SP, Lim SC, González-Roca E, Ruiz-Ortiz E, et al. Brief Report: First Identification of Intrafamilial Recurrence of Blau Syndrome due to Gonosomal NOD2 Mosaicism. *Arthritis & Rheumatology* (Hoboken, NJ). 2016 Apr;68(4):1039–44.
  14. de Inocencio J, Mensa-Vilaro A, Tejada-Palacios P, Enriquez-Merayo E, González-Roca E, Magri G, et al. Somatic NOD2 mosaicism in Blau syndrome. *J Allergy Clin Immunol*. 2015 Aug;136(2):484-487.e2.
  15. Harapas CR, Steiner A, Davidson S, Masters SL. An Update on Autoinflammatory Diseases: Inflammasomopathies. *Curr Rheumatol Rep*. 2018 May 30;20(7):40.
  16. Aksentijevich I, Zhou Q. NF- $\kappa$ B Pathway in Autoinflammatory Diseases: Dysregulation of Protein Modifications by Ubiquitin Defines a New Category of Autoinflammatory Diseases. *Front Immunol*. 2017;8:399.
  17. Kattah MG, Malynn BA, Ma A. Ubiquitin-Modifying Enzymes and Regulation of the Inflammasome. *J Mol Biol*. 2017 Nov 10;429(22):3471–85.
  18. Aeschlimann FA, Batu ED, Canna SW, Go E, Gül A, Hoffmann P, et al. A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF- $\kappa$ B-mediated autoinflammatory disease. *Ann Rheum Dis*. 2018 May;77(5):728–35.
  19. Zhou Q, Wang H, Schwartz DM, Stoffels M, Park YH, Zhang Y, et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. *Nat Genet*. 2016 Jan;48(1):67–73.
  20. Zhou Q, Yu X, Demirkaya E, Deutch N, Stone D, Tsai WL, et al. Biallelic hypomorphic mutations in a linear deubiquitinase define otulipenia, an early-onset autoinflammatory disease. *Proc Natl Acad Sci USA*. 2016 Sep 6;113(36):10127–32.
  21. Shigemura T, Kaneko N, Kobayashi N, Kobayashi K, Takeuchi Y, Nakano N, et al. Novel heterozygous C243Y A20/TNFAIP3 gene mutation is responsible for chronic inflammation in autosomal-dominant Behçet's disease. *RMD Open*. 2016;2(1):e000223.

22. Kadowaki T, Ohnishi H, Kawamoto N, Hori T, Nishimura K, Kobayashi C, et al. Haploinsufficiency of A20 causes autoinflammatory and autoimmune disorders. *J Allergy Clin Immunol*. 2018 Apr;141(4):1485-1488.e11.
23. Boisson B, Laplantine E, Prando C, Giliani S, Israelsson E, Xu Z, et al. Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. *Nat Immunol*. 2012 Dec;13(12):1178–86.
24. Boisson B, Laplantine E, Dobbs K, Cobat A, Tarantino N, Hazen M, et al. Human HOIP and LUBAC deficiency underlies autoinflammation, immunodeficiency, amylopectinosis, and lymphangiectasia. *J Exp Med*. 2015 Jun 1;212(6):939–51.
25. Damgaard RB, Walker JA, Marco-Casanova P, Morgan NV, Titheradge HL, Elliott PR, et al. The Deubiquitinase OTULIN Is an Essential Negative Regulator of Inflammation and Autoimmunity. *Cell*. 2016 Aug 25;166(5):1215-1230.e20.
26. Fayand A, Sarrabay G, Belot A, Hentgen V, Kone-Paut I, Grateau G, et al. [Multiple facets of ADA2 deficiency: Vasculitis, auto-inflammatory disease and immunodeficiency: A literature review of 135 cases from literature]. *Rev Med Interne*. 2018 Apr;39(4):297–306.
27. Davidson S, Steiner A, Harapas CR, Masters SL. An Update on Autoinflammatory Diseases: Interferonopathies. *Curr Rheumatol Rep*. 2018 May 30;20(7):38.
28. Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, et al. Criteria for the diagnosis of familial Mediterranean fever. *Arthritis Rheum*. 1997 Oct;40(10):1879–85.
29. Georgin-Lavialle S, Hentgen V, Stankovic Stojanovic K, Bachmeyer C, Rodrigues F, Savey L, et al. [Familial Mediterranean fever]. *Rev Med Interne*. 2018 Apr;39(4):240–55.
30. Özen S, Batu ED, Demir S. Familial Mediterranean Fever: Recent Developments in Pathogenesis and New Recommendations for Management. *Front Immunol*. 2017;8:253.
31. Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, et al. EULAR recommendations for the management of familial Mediterranean fever. *Ann Rheum Dis*. 2016 Apr;75(4):644–51.
32. Padeh S, Berkun Y. Familial Mediterranean fever. *Curr Opin Rheumatol*. 2016 Sep;28(5):523–9.
33. Ozen S, Batu ED. The myths we believed in familial Mediterranean fever: what have we learned in the past years? *Semin Immunopathol*. 2015 Jul;37(4):363–9.

34. Hentgen V, Grateau G, Kone-Paut I, Livneh A, Padeh S, Rozenbaum M, et al. Evidence-based recommendations for the practical management of Familial Mediterranean Fever. *Semin Arthritis Rheum*. 2013 Dec;43(3):387–91.
35. Alghamdi M. Familial Mediterranean fever, review of the literature. *Clin Rheumatol*. 2017 Aug;36(8):1707–13.
36. Livneh A, Zemer D, Langevitz P, Laor A, Sohar E, Pras M. Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome. *Arthritis Rheum*. 1994 Dec;37(12):1804–11.
37. Hentgen V, Grateau G, Kone-Paut I, Livneh A, Padeh S, Rozenbaum M, et al. Evidence-based recommendations for the practical management of Familial Mediterranean Fever. *Semin Arthritis Rheum*. 2013 Dec;43(3):387–91.
38. Cazeneuve C, Ajrapetyan H, Papin S, Roudot-Thoraval F, Geneviève D, Mndjoyan E, et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. *Am J Hum Genet*. 2000 Nov;67(5):1136–43.
39. Altunoğlu A, Erten Ş, Canoz MB, Yuksel A, Ceylan GG, Balci S, et al. Phenotype 2 familial mediterranean fever: evaluation of 22 case series and review of the literature on phenotype 2 FMF. *Ren Fail*. 2013;35(2):226–30.
40. Marek-Yagel D, Berkun Y, Padeh S, Abu A, Reznik-Wolf H, Livneh A, et al. Clinical disease among patients heterozygous for familial Mediterranean fever. *Arthritis Rheum*. 2009 Jun;60(6):1862–6.
41. Hentgen V, Grateau G, Stankovic-Stojanovic K, Amselem S, Jéru I. Familial Mediterranean fever in heterozygotes: are we able to accurately diagnose the disease in very young children? *Arthritis Rheum*. 2013 Jun;65(6):1654–62.
42. Sönmez HE, Batu ED, Bilginer Y, Özen S. Discontinuing colchicine in symptomatic carriers for MEFV (Mediterranean FeVer) variants. *Clin Rheumatol*. 2017 Feb;36(2):421–5.
43. Rowczenio DM, Iancu DS, Trojer H, Gilbertson JA, Gillmore JD, Wechalekar AD, et al. Autosomal dominant familial Mediterranean fever in Northern European Caucasians associated with deletion of p.M694 residue—a case series and genetic exploration. *Rheumatology (Oxford)*. 2017 Feb;56(2):209–13.
44. Sarrabay G, Touitou I. Dominant familial Mediterranean fever. *Rheumatology (Oxford)*. 2017 Feb;56(2):173–5.

45. Stoffels M, Szperl A, Simon A, Netea MG, Plantinga TS, van Deuren M, et al. MEFV mutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease. *Ann Rheum Dis*. 2014 Feb;73(2):455–61.
46. Aldea A, Campistol JM, Arostegui JI, Rius J, Maso M, Vives J, et al. A severe autosomal-dominant periodic inflammatory disorder with renal AA amyloidosis and colchicine resistance associated to the MEFV H478Y variant in a Spanish kindred: an unusual familial Mediterranean fever phenotype or another MEFV-associated periodic inflammatory disorder? *Am J Med Genet A*. 2004 Jan 1;124A(1):67–73.
47. Nabil H, Zayed A, State O, Badawy A. Pregnancy outcome in women with familial Mediterranean fever. *J Obstet Gynaecol*. 2012 Nov;32(8):756–9.
48. Mijatovic V, Hompes PGA, Wouters MG AJ. Familial Mediterranean fever and its implications for fertility and pregnancy. *Eur J Obstet Gynecol Reprod Biol*. 2003 Jun 10;108(2):171–6.
49. Indraratna PL, Virk S, Gurram D, Day RO. Use of colchicine in pregnancy: a systematic review and meta-analysis. *Rheumatology (Oxford)*. 2017 Sep 23;
50. Ben-Chetrit E, Ben-Chetrit A, Berkun Y, Ben-Chetrit E. Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: is amniocentesis justified? *Arthritis Care Res (Hoboken)*. 2010 Feb;62(2):143–8.
51. Ben-Chetrit E, Levy M. Reproductive system in familial Mediterranean fever: an overview. *Ann Rheum Dis*. 2003 Oct;62(10):916–9.
52. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. *N Engl J Med*. 1986 Apr 17;314(16):1001–5.
53. Quartier P, Rodrigues F, Georgin-Lavialle S. [Cryopyrin-associated periodic syndromes]. *Rev Med Interne*. 2018 Apr;39(4):287–96.
54. Kuemmerle-Deschner JB, Ozen S, Tyrrell PN, Kone-Paut I, Goldbach-Mansky R, Lachmann H, et al. Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). *Ann Rheum Dis*. 2017 Jun;76(6):942–7.
55. Rowczenio DM, Gomes SM, Aróstegui JI, Mensa-Vilaro A, Omoyinmi E, Trojer H, et al. Late-Onset Cryopyrin-Associated Periodic Syndromes Caused by Somatic NLRP3 Mosaicism-UK Single Center Experience. *Front Immunol*. 2017;8:1410.
56. Labrousse M, Kevorkian-Verguet C, Boursier G, Rowczenio D, Maurier F, Lazaro E, et al. Mosaicism in autoinflammatory diseases: Cryopyrin-associated periodic

- syndromes (CAPS) and beyond. A systematic review. *Crit Rev Clin Lab Sci*. 2018 Sep;55(6):432–42.
57. Kuemmerle-Deschner JB, Hofer F, Endres T, Kortus-Goetze B, Blank N, Weißbarth-Riedel E, et al. Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome. *Rheumatology (Oxford)*. 2016 Apr;55(4):689–96.
  58. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. *N Engl J Med*. 2009 Jun 4;360(23):2416–25.
  59. Kuemmerle-Deschner JB, Haug I. Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians. *Ther Adv Musculoskelet Dis*. 2013 Dec;5(6):315–29.
  60. ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, et al. Recommendations for the management of autoinflammatory diseases. *Ann Rheum Dis*. 2015 Sep;74(9):1636–44.
  61. Georgin-Lavialle S, Kone-Paut I, Delaleu J, Sarrabay G, Grateau G, Touitou I, et al. [Tumor necrosis receptor associated periodic syndrome (TRAPS): State of the art]. *Rev Med Interne*. 2018 Apr;39(4):256–64.
  62. McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. *Cell*. 1999 Apr 2;97(1):133–44.
  63. Federici S, Sormani MP, Ozen S, Lachmann HJ, Amaryan G, Woo P, et al. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. *Ann Rheum Dis*. 2015 May;74(5):799–805.
  64. Grimwood C, Despert V, Jeru I, Hentgen V. On-demand treatment with anakinra: a treatment option for selected TRAPS patients. *Rheumatology (Oxford)*. 2015 Sep;54(9):1749–51.
  65. De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. *N Engl J Med*. 2018 17;378(20):1908–19.
  66. Galeotti C, Georgin-Lavialle S, Sarrabay G, Touitou I, Koné-Paut I. [Mevalonate kinase deficiency in 2016]. *Rev Med Interne*. 2018 Apr;39(4):265–70.
  67. van der Hilst JCH, Bodar EJ, Barron KS, Frenkel J, Drenth JPH, van der Meer JWM, et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients

- with hyperimmunoglobulinemia D syndrome. *Medicine (Baltimore)*. 2008 Nov;87(6):301–10.
68. Bader-Meunier B, Florkin B, Sibilia J, Acquaviva C, Hachulla E, Grateau G, et al. Mevalonate kinase deficiency: a survey of 50 patients. *Pediatrics*. 2011 Jul;128(1):e152-159.
69. Ter Haar NM, Jeyaratnam J, Lachmann HJ, Simon A, Brogan PA, Doglio M, et al. The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry. *Arthritis & Rheumatology (Hoboken, NJ)*. 2016 Nov;68(11):2795–805.
70. Ammouri W, Cuisset L, Rouaghe S, Rolland M-O, Delpech M, Grateau G, et al. Diagnostic value of serum immunoglobulinaemia D level in patients with a clinical suspicion of hyper IgD syndrome. *Rheumatology (Oxford)*. 2007 Oct;46(10):1597–600.
71. Park YH, Wood G, Kastner DL, Chae JJ. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. *Nat Immunol*. 2016;17(8):914–21.
72. Rafiq NK, Lachmann H, Joensen F, Herlin T, Brogan PA. Tocilizumab for the Treatment of Mevalonate Kinase Deficiency. *Case Rep Pediatr*. 2018;2018:3514645.
73. Deshayes S, Georgin-Lavialle S, Hot A, Durel C-A, Hachulla E, Rouanes N, et al. Efficacy of Continuous Interleukin 1 Blockade in Mevalonate Kinase Deficiency: A Multicenter Retrospective Study in 13 Adult Patients and Literature Review. *J Rheumatol*. 2018 Mar;45(3):425–9.
74. Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. *N Engl J Med*. 2014 Mar 6;370(10):921–31.
75. Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. *N Engl J Med*. 2014 Mar 6;370(10):911–20.
76. Meyts I, Aksentjevich I. Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment. *J Clin Immunol*. 2018 Jul;38(5):569–78.
77. Van Montfrans JM, Hartman EAR, Braun KPJ, Hennekam EAM, Hak EA, Nederkoorn PJ, et al. Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. *Rheumatology (Oxford)*. 2016 May;55(5):902–10.

78. Caorsi R, Penco F, Grossi A, Insalaco A, Omenetti A, Alessio M, et al. ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. *Ann Rheum Dis.* 2017 Oct;76(10):1648–56.
79. Hashem H, Kelly SJ, Ganson NJ, Hershfield MS. Deficiency of Adenosine Deaminase 2 (DADA2), an Inherited Cause of Polyarteritis Nodosa and a Mimic of Other Systemic Rheumatologic Disorders. *Curr Rheumatol Rep.* 2017 Oct 5;19(11):70.
80. Zavialov AV, Gracia E, Glaichenhaus N, Franco R, Zavialov AV, Lauvau G. Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. *J Leukoc Biol.* 2010 Jan 8;88(2):279–90.
81. Belot A, Wassmer E, Twilt M, Lega J-C, Zeef LA, Oojageer A, et al. Mutations in CECR1 associated with a neutrophil signature in peripheral blood. *Pediatr Rheumatol Online J.* 2014;12:44.
82. Uettwiller F, Sarrabay G, Rodero MP, Rice GI, Lagrue E, Marot Y, et al. ADA2 deficiency: case report of a new phenotype and novel mutation in two sisters. *RMD Open.* 2016;2(1):e000236.
83. Skrabl-Baumgartner A, Plecko B, Schmidt WM, König N, Hershfield M, Gruber-Sedlmayr U, et al. Autoimmune phenotype with type I interferon signature in two brothers with ADA2 deficiency carrying a novel CECR1 mutation. *Pediatr Rheumatol Online J.* 2017 Aug 22;15(1):67.
84. Rama M, Duflos C, Melki I, Bessis D, Bonhomme A, Martin H, et al. A decision tree for the genetic diagnosis of deficiency of adenosine deaminase 2 (DADA2): a French reference centres experience. *Eur J Hum Genet.* 2018 Jul;26(7):960–71.
85. Springer JM, Gierer SA, Jiang H, Kleiner D, Deutch N, Ombrello AK, et al. Deficiency of Adenosine Deaminase 2 in Adult Siblings: Many Years of a Misdiagnosed Disease With Severe Consequences. *Front Immunol.* 2018;9:1361.
86. Schepp J, Proietti M, Frede N, Buchta M, Hübscher K, Rojas Restrepo J, et al. Screening of 181 Patients With Antibody Deficiency for Deficiency of Adenosine Deaminase 2 Sheds New Light on the Disease in Adulthood. *Arthritis & Rheumatology (Hoboken, NJ).* 2017 Aug;69(8):1689–700.
87. Schepp J, Bulashevskaya A, Mannhardt-Laakmann W, Cao H, Yang F, Seidl M, et al. Deficiency of Adenosine Deaminase 2 Causes Antibody Deficiency. *J Clin Immunol.* 2016 Apr;36(3):179–86.

88. Van Eyck L, Hershfield MS, Pombal D, Kelly SJ, Ganson NJ, Moens L, et al. Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency. *J Allergy Clin Immunol*. 2015 Jan;135(1):283-287.e5.
89. Hashem H, Kumar AR, Müller I, Babor F, Bredius R, Dalal J, et al. Hematopoietic stem cell transplantation rescues the hematological, immunological and vascular phenotype in DADA2. *Blood*. 2017 Oct 3;
90. Van Nieuwenhove E, Humblet-Baron S, Van Eyck L, De Somer L, Dooley J, Tousseyn T, et al. ADA2 Deficiency Mimicking Idiopathic Multicentric Castleman Disease. *Pediatrics*. 2018 Sep;142(3).
91. Kitamura A, Sasaki Y, Abe T, Kano H, Yasutomo K. An inherited mutation in NLRC4 causes autoinflammation in human and mice. *J Exp Med*. 2014 Nov 17;211(12):2385–96.
92. Romberg N, Al Moussawi K, Nelson-Williams C, Stiegler AL, Loring E, Choi M, et al. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. *Nat Genet*. 2014 Oct;46(10):1135–9.
93. Canna SW, de Jesus AA, Gouni S, Brooks SR, Marrero B, Liu Y, et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. *Nat Genet*. 2014 Oct;46(10):1140–6.
94. Rodrigues F, Hentgen V, Bachmeyer C, Kone-Paut I, Belot A, Grateau G, et al. [NLRC4 associated autoinflammatory diseases: A systematic review of the current literature]. *Rev Med Interne*. 2018 Apr;39(4):279–86.
95. Canna SW, Girard C, Malle L, de Jesus A, Romberg N, Kelsen J, et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. *J Allergy Clin Immunol*. 2017 May;139(5):1698–701.
96. Romberg N, Vogel TP, Canna SW. NLRC4 inflammasomopathies. *Curr Opin Allergy Clin Immunol*. 2017 Sep 27;
97. Jéru I, Duquesnoy P, Fernandes-Alnemri T, Cochet E, Yu JW, Lackmy-Port-Lis M, et al. Mutations in NALP12 cause hereditary periodic fever syndromes. *Proc Natl Acad Sci USA*. 2008 Feb 5;105(5):1614–9.
98. Shen M, Tang L, Shi X, Zeng X, Yao Q. NLRP12 autoinflammatory disease: a Chinese case series and literature review. *Clin Rheumatol*. 2017 Jul;36(7):1661–7.



99. De Pieri C, Vuch J, Athanasakis E, Severini GM, Crovella S, Bianco AM, et al. F402L variant in NLRP12 in subjects with undiagnosed periodic fevers and in healthy controls. *Clin Exp Rheumatol*. 2014 Dec;32(6):993–4.
100. Kostik MM, Suspitsin EN, Guseva MN, Levina AS, Kazantseva AY, Sokolenko AP, et al. Multigene sequencing reveals heterogeneity of NLRP12-related autoinflammatory disorders. *Rheumatol Int*. 2018 May;38(5):887–93.
101. Jéru I, Cochet E, Duquesnoy P, Hentgen V, Copin B, Mitjavila-Garcia MT, et al. Brief Report: Involvement of TNFRSF11A molecular defects in autoinflammatory disorders. *Arthritis & Rheumatology (Hoboken, NJ)*. 2014 Sep;66(9):2621–7.
102. Kallinich T, Thorwarth A, von Stuckrad S-L, Rösen-Wolff A, Luksch H, Hundsdoerfer P, et al. Juvenile arthritis caused by a novel FAMIN (LACC1) mutation in two children with systemic and extended oligoarticular course. *Pediatr Rheumatol Online J*. 2016 Nov 24;14(1):63.
103. Wakil SM, Monies DM, Abouelhoda M, Al-Tassan N, Al-Dusery H, Naim EA, et al. Association of a mutation in LACC1 with a monogenic form of systemic juvenile idiopathic arthritis. *Arthritis & Rheumatology (Hoboken, NJ)*. 2015 Jan;67(1):288–95.
104. Wouters CH, Maes A, Foley KP, Bertin J, Rose CD. Blau syndrome, the prototypic auto-inflammatory granulomatous disease. *Pediatr Rheumatol Online J*. 2014;12:33.
105. Yao Q, Shen B. A Systematic Analysis of Treatment and Outcomes of NOD2-Associated Autoinflammatory Disease. *Am J Med*. 2017 Mar;130(3):365.e13-365.e18.
106. Yao Q, Shen M, McDonald C, Lachawan F, Moran R, Shen B. NOD2-associated autoinflammatory disease: a large cohort study. *Rheumatology (Oxford)*. 2015 Oct;54(10):1904–12.
107. Yao Q, Zhou L, Cusumano P, Bose N, Piliang M, Jayakar B, et al. A new category of autoinflammatory disease associated with NOD2 gene mutations. *Arthritis Res Ther*. 2011;13(5):R148.
108. Holzinger D, Fassl SK, de Jager W, Lohse P, Röhrig UF, Gattorno M, et al. Single amino acid charge switch defines clinically distinct proline-serine-threonine phosphatase-interacting protein 1 (PSTPIP1)-associated inflammatory diseases. *J Allergy Clin Immunol*. 2015 Nov;136(5):1337–45.
109. Lindwall E, Singla S, Davis WE, Quinet RJ. Novel PSTPIP1 gene mutation in a patient with pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) syndrome. *Semin Arthritis Rheum*. 2015 Aug;45(1):91–3.

110. Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)--a new autoinflammatory syndrome distinct from PAPA syndrome. *J Am Acad Dermatol*. 2012 Mar;66(3):409–15.
111. Geusau A, Mothes-Luksch N, Nahavandi H, Pickl WF, Wise CA, Pourpak Z, et al. Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment. *JAMA Dermatol*. 2013 Feb;149(2):209–15.
112. Zeeli T, Padalon-Brauch G, Ellenbogen E, Gat A, Sarig O, Sprecher E. Pyoderma gangrenosum, acne and ulcerative colitis in a patient with a novel mutation in the PSTPIP1 gene. *Clin Exp Dermatol*. 2015 Jun;40(4):367–72.
113. Stern SM, Ferguson PJ. Autoinflammatory bone diseases. *Rheum Dis Clin North Am*. 2013 Nov;39(4):735–49.
114. Rao AP, Gopalakrishna DB, Bing X, Ferguson PJ. Phenotypic Variability in Majeed Syndrome. *J Rheumatol*. 2016 Jun;43(6):1258–9.
115. Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. *N Engl J Med*. 2009 Jun 4;360(23):2426–37.
116. Rossi-Semerano L, Piram M, Chiaverini C, De Ricaud D, Smahi A, Koné-Paut I. First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra. *Pediatrics*. 2013 Oct;132(4):e1043-1047.
117. Bonekamp N, Caorsi R, Viglizzo GM, Graaf M de, Minoia F, Grossi A, et al. High-dose ustekinumab for severe childhood deficiency of interleukin-36 receptor antagonist (DITRA). *Ann Rheum Dis*. 2017 Sep 2;
118. Grandemange S, Sanchez E, Louis-Plence P, Tran Mau-Them F, Bessis D, Coubes C, et al. A new autoinflammatory and autoimmune syndrome associated with NLRP1 mutations: NAIAD (NLRP1-associated autoinflammation with arthritis and dyskeratosis). *Ann Rheum Dis*. 2017 Jul;76(7):1191–8.
119. Takeichi T, Sugiura K, Nomura T, Sakamoto T, Ogawa Y, Oiso N, et al. Pityriasis Rubra Pilaris Type V as an Autoinflammatory Disease by CARD14 Mutations. *JAMA Dermatol*. 2017 Jan 1;153(1):66–70.
120. Fuchs-Telem D, Sarig O, van Steensel MAM, Isakov O, Israeli S, Nousbeck J, et al. Familial pityriasis rubra pilaris is caused by mutations in CARD14. *Am J Hum Genet*. 2012 Jul 13;91(1):163–70.

121. Liu Y, Gao M, Lv Y, Yang X, Ren Y, Jiang T, et al. Confirmation by exome sequencing of the pathogenic role of NCSTN mutations in acne inversa (hidradenitis suppurativa). *J Invest Dermatol*. 2011 Jul;131(7):1570–2.
122. Faraji Zonooz M, Sabbagh-Kermani F, Fattahi Z, Fadaee M, Akbari MR, Amiri R, et al. Whole Genome Linkage Analysis Followed by Whole Exome Sequencing Identifies Nicastrin (NCSTN) as a Causative Gene in a Multiplex Family with  $\gamma$ -Secretase Spectrum of Autoinflammatory Skin Phenotypes. *J Invest Dermatol*. 2016 Jun;136(6):1283–6.
123. Miskinyte S, Nassif A, Merabtene F, Ungeheuer M-N, Join-Lambert O, Jais J-P, et al. Nicastrin mutations in French families with hidradenitis suppurativa. *J Invest Dermatol*. 2012 Jun;132(6):1728–30.
124. Vinkel C, Thomsen SF. Autoinflammatory syndromes associated with hidradenitis suppurativa and/or acne. *Int J Dermatol*. 2017 Aug;56(8):811–8.
125. Marzano AV, Ceccherini I, Gattorno M, Fanoni D, Caroli F, Rusmini M, et al. Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases. *Medicine (Baltimore)*. 2014 Dec;93(27):e187.
126. Steiner A, Harapas CR, Masters SL, Davidson S. An Update on Autoinflammatory Diseases: Relopathies. *Curr Rheumatol Rep*. 2018 May 30;20(7):39.
127. Berteau F, Rouviere B, Delluc A, Nau A, Le Berre R, Sarrabay G, et al. Autosomic dominant familial Behçet disease and haploinsufficiency A20: A review of the literature. *Autoimmun Rev*. 2018 Aug;17(8):809–15.
128. Aksentijevich I, Zhou Q. NF- $\kappa$ B Pathway in Autoinflammatory Diseases: Dysregulation of Protein Modifications by Ubiquitin Defines a New Category of Autoinflammatory Diseases. *Front Immunol*. 2017;8:399.
129. Jain A, Misra DP, Sharma A, Wakhlu A, Agarwal V, Negi VS. Vasculitis and vasculitis-like manifestations in monogenic autoinflammatory syndromes. *Rheumatol Int*. 2017 Oct 14;
130. Picard C, Belot A. [Type I interferonopathies. Literature review]. *Rev Med Interne*. 2016 Sep 19;
131. Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Sanchez GAM, et al. Activated STING in a vascular and pulmonary syndrome. *N Engl J Med*. 2014 Aug 7;371(6):507–18.

132. Crow YJ, Casanova J-L. STING-associated vasculopathy with onset in infancy--a new interferonopathy. *N Engl J Med*. 2014 Aug 7;371(6):568–71.
133. Boisson B, Laplantine E, Dobbs K, Cobat A, Tarantino N, Hazen M, et al. Human HOIP and LUBAC deficiency underlies autoinflammation, immunodeficiency, amylopectinosis, and lymphangiectasia. *J Exp Med*. 2015 Jun 1;212(6):939–51.
134. Ombrello MJ, Remmers EF, Sun G, Freeman AF, Datta S, Torabi-Parizi P, et al. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. *N Engl J Med*. 2012 Jan 26;366(4):330–8.
135. Zhou Q, Lee G-S, Brady J, Datta S, Katan M, Sheikh A, et al. A hypermorphic missense mutation in PLCG2, encoding phospholipase C $\gamma$ 2, causes a dominantly inherited autoinflammatory disease with immunodeficiency. *Am J Hum Genet*. 2012 Oct 5;91(4):713–20.
136. Standing ASI, Malinova D, Hong Y, Record J, Moulding D, Blundell MP, et al. Autoinflammatory periodic fever, immunodeficiency, and thrombocytopenia (PFIT) caused by mutation in actin-regulatory gene WDR1. *J Exp Med*. 2017 Jan;214(1):59–71.
137. Chakraborty PK, Schmitz-Abe K, Kennedy EK, Mamady H, Naas T, Durie D, et al. Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). *Blood*. 2014 Oct 30;124(18):2867–71.
138. Wiseman DH, May A, Jolles S, Connor P, Powell C, Heeney MM, et al. A novel syndrome of congenital sideroblastic anemia, B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD). *Blood*. 2013 Jul 4;122(1):112–23.
139. Yao Q, Shen M, Fernandez J. NOD2-associated autoinflammatory disease and immune deficiency. *J Allergy Clin Immunol Pract*. 2016 Aug;4(4):780–2.
140. Shi C, Wang F, Tong A, Zhang X-Q, Song H-M, Liu Z-Y, et al. NFKB2 mutation in common variable immunodeficiency and isolated adrenocorticotrophic hormone deficiency: A case report and review of literature. *Medicine (Baltimore)*. 2016 Oct;95(40):e5081.
141. Chen K, Coonrod EM, Kumánovics A, Franks ZF, Durtschi JD, Margraf RL, et al. Germline mutations in NFKB2 implicate the noncanonical NF- $\kappa$ B pathway in the pathogenesis of common variable immunodeficiency. *Am J Hum Genet*. 2013 Nov 7;93(5):812–24.
142. Molho-Pessach V, Agha Z, Aamar S, Glaser B, Doviner V, Hiller N, et al. The H syndrome: a genodermatosis characterized by indurated, hyperpigmented, and

- hypertrichotic skin with systemic manifestations. *J Am Acad Dermatol*. 2008 Jul;59(1):79–85.
143. Molho-Pessach V, Lerer I, Abeliovich D, Agha Z, Abu Libdeh A, Broshtilova V, et al. The H syndrome is caused by mutations in the nucleoside transporter hENT3. *Am J Hum Genet*. 2008 Oct;83(4):529–34.
  144. Molho-Pessach V, Ramot Y, Camille F, Doviner V, Babay S, Luis SJ, et al. H syndrome: the first 79 patients. *J Am Acad Dermatol*. 2014 Jan;70(1):80–8.
  145. Rossbach H-C, Dalence C, Wynn T, Tebbi C. Faisalabad histiocytosis mimics Rosai-Dorfman disease: brothers with lymphadenopathy, intrauterine fractures, short stature, and sensorineural deafness. *Pediatr Blood Cancer*. 2006 Oct 15;47(5):629–32.
  146. Emile J-F, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. *Blood*. 2016 02;127(22):2672–81.
  147. Bloom JL, Lin C, Imundo L, Guthery S, Stepenaskie S, Galambos C, et al. H syndrome: 5 new cases from the United States with novel features and responses to therapy. *Pediatr Rheumatol Online J*. 2017 Oct 17;15(1):76.
  148. Rafiq NK, Hussain K, Brogan PA. Tocilizumab for the Treatment of SLC29A3 Mutation Positive PHID Syndrome. *Pediatrics*. 2017 Nov;140(5).
  149. Gusdorf L, Lipsker D. Schnitzler Syndrome: a Review. *Curr Rheumatol Rep*. 2017 Aug;19(8):46.
  150. de Koning HD, van Gijn ME, Stoffels M, Jongekrijg J, Zeeuwen PLJM, Elferink MG, et al. Myeloid lineage-restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndrome. *J Allergy Clin Immunol*. 2015 Feb;135(2):561–4.
  151. Rowczenio DM, Pathak S, Arostegui JI, Mensa-Vilaro A, Omoyinmi E, Brogan P, et al. Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome. *Blood*. 2018 Mar 1;131(9):974–81.
  152. Cimaz R. Systemic-onset juvenile idiopathic arthritis. *Autoimmun Rev*. 2016 Sep;15(9):931–4.
  153. Fautrel B. Adult-onset Still disease. *Best Pract Res Clin Rheumatol*. 2008 Oct;22(5):773–92.
  154. Theodoropoulou K, Georgin-Lavialle S. [Systemic juvenile onset idiopathic arthritis and adult onset still disease]. *Rev Med Suisse*. 2018 Feb 14;14(594):372–7.

155. André MFJ, Piette J-C, Kémény J-L, Ninet J, Jégo P, Delèvaux I, et al. Aseptic abscesses: a study of 30 patients with or without inflammatory bowel disease and review of the literature. *Medicine (Baltimore)*. 2007 May;86(3):145–61.
156. André M, Aumaître O. [Aseptic abscesses syndrome]. *Rev Med Interne*. 2011 Nov;32(11):678–88.
157. Hofer M, Pillet P, Cochard M-M, Berg S, Krol P, Kone-Paut I, et al. International periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis syndrome cohort: description of distinct phenotypes in 301 patients. *Rheumatology (Oxford)*. 2014 Jun;53(6):1125–9.
158. Cantarini L, Vitale A, Sicignano LL, Emmi G, Verrecchia E, Patisso I, et al. Diagnostic Criteria for Adult-Onset Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome. *Front Immunol*. 2017;8:1018.

## Tables.

**Table 1. Orientation of AID from clinical, biological or histological main features.**

**Table 2. Main characteristics of HA20 with autoinflammatory features from literature.**

**Table 3. A diagnostic-check-list for AID.**

## Figures legends

**Figure 1. Main known pathophysiological pathways in monogenic autoinflammatory diseases.**

Panel A. In the first described and most known monogenic autoinflammatory diseases, there is an excessive production of pro-inflammatory cytokines (especially interleukins 1, 6, 18 and TNF $\alpha$ ) by pyrin or NLRP3 inflammasomes. In mevalonate kinase deficiency the activation of the pathway also results in stimulation of pyrin. The danger signal can also come from a failure of protein folding as in the mutations of *TNFRSF1A* (TRAPS syndrome) which leads to increased secretion of oxygenated radicals (ROS) and thus activate inflammasomes. Recently discovered autoinflammatory diseases involve other inflammasomes such as NLRP1 or NLRC4-NAIP. The inflammasome activation can also come from an imbalance of endogenous antagonists in the rare mutations of *IL1RN* (DIRA syndrome) or *IL36RN* (DITRA syndrome).

Panel B. In *ADA2* deficiency, there is an imbalance in the balance of macrophages M1/M2 with an excess of pro-inflammatory macrophages and vasculitis.

Panel C. Diseases that result in stimulation of NF-KB pathway are either related to gain of function of activators (*NOD2* mutations) or loss of function of inhibitors such as the LUBAC, OTULIN and HA20 ubiquitin-ligases.

Panel D. Interferonopathies have several entities where mutations induce overexpression of the interferon gene. In those diseases there is an excess of interferon and pro-inflammatory cytokines.

**Figure 2. Most frequent cutaneous and mucosal lesions in AID.**

Panel A: Erysipelas-like erythema in the ankle of a patient during an attack of familial Mediterranean fever.

Panel B: Urticaria in a patient with cryopyrinopathy.

Panel C: Oral aphtae in a patient with mevalonate kinase deficiency.

Panel D: fugitive erythematous lesion in a patient with adult onset Still's disease.

### **Figure 3. Main features of DADA2**

This figure compiles the most important elements to know on DADA2. On panel A are represented the main clinical features, in red the most frequent and most specific compared to other AID. On panel B: a family tree showing typical autosomal recessive transmission – with consanguineous parents – which is the most frequent type of transmission in DADA2. On panel C are represented strokes that usually appear early in life. On panel D is represented an hypogammaglobulinemia, since immunodeficiency mimicking common variable immunodeficiency is one of the cardinal manifestations of DADA2. On panel E is represented a cutaneous livedo, a frequent clinical feature of the diseases as well as abdominal pain (panel F) and arthromyalgia (panel G).

### **Figure 4. Main chronological features of AID.**

The main chronological features that can help to guide the diagnosis to one AID or another are represented on this figure. On panel A is represented the usual attack length in familial Mediterranean fever (2-4 days); on panel B is represented the specificity of PFAPA with very often the same interval of days between 2 attacks; On panel C is represented this long attack length of TRAPS between 7 and 21 days; On the panel D is represented Still disease with usually very long attack from 15 to 30 days, and even more when not treated. It emphasizes the importance of asking of attack length and the interval between 2 crises.

### **Figure 5. Main clinical features of the most frequent AID.**

The main features during crisis of the four historical monogenic AID are represented on 4 panels: A for familial Mediterranean fever; B for *NLRP3*-associated autoinflammatory disease (*NLRP3*-AID); C for TNFRSF1A receptor associated periodic syndrome; D for mevalonate kinase deficiency. For each disease the main symptoms are written in red and the frequency of amyloidosis is written at the bottom of each subject.



**Abbreviations:**

APLAID: Autoinflammation and PLCg2-associated Antibody deficiency and Immune Dysregulation

CAMPS: CARD14-mediated pustular psoriasis= *CARD14*-associated psoriasis

CANDLE: chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome

CAPS: cryopyrin-associated periodic fever syndrome= *NLRP3*-associated autoinflammatory disease (*NLRP3*-AID)

CINCA: Chronic infantile neurological, cutaneous and articular syndrome

DIRA: Deficiency of the IL-1 receptor antagonist

DITRA: Deficiency of the IL-36 receptor antagonist

DUB: deubiquitinase

FCAS: Familial cold autoinflammatory syndrome

FCAS2: Familial cold autoinflammatory syndrome 2 (*NLRP12*-associated autoinflammatory disease).

FMF: Familial Mediterranean fever

HA20: A20 haploinsufficiency

LUBAC: Linear ubiquitin chain assembling complex

MKD: mevalonate kinase deficiency

MWS: Muckle Wells syndrome

NAIAD: *NLRP1*-associated autoinflammation with arthritis and dyskeratosis

NAID: *NOD2*-associated autoinflammatory diseases

NLRC4-MAS: *NLRC4* associated macrophage activation syndrome

ORAS: Otulin related autoinflammatory syndrome

PAAND: Pyrin-associated autoinflammation with neutrophilic dermatosis

PAID: PSTPIP1-associated autoinflammatory diseases

PAMI: PSTPIP1-Associated Myeloid-related-proteinemia Inflammatory syndrome

PAPA: syndrome pyogenic arthritis, pyoderma gangrenosum and acne

PAPASH: PSTPIP1-associated Pyoderma gangrenosum, Acne and Hidradenitis Suppurativa

PAC: Pyoderma gangrenosum, Acne and ulcerative Colitis

PFAPA: Periodic Fever Aphthous Stomatitis Pharyngitis Adenitis

PFIT: Periodic Fever with Immunodeficiency and Thrombocytopenia


PLAID: PLCg2-associated Antibody deficiency and Immune Dysregulation

SAVI: STING-associated vasculopathy with onset in infancy


SIFD: Sideroblastic anemia with B-cell Immunodeficiency, periodic Fevers and Developmental delay

TNFRSF11A: TNF11 $\alpha$ -Receptor associated periodic syndrome

TRAPS: TNF-Receptor associated periodic syndrome

**A****TRAPS**

**INFLAMMASOMOPATHIES:**  
 FMF, CAPS, MKD, PAAND, PAPA



**Imbalance of endogenous antagonists:**  
 Mutations of *IL1RN*, *IL36RN*


**INFLAMMATION**  
 In monocyte/macrophages

**B**

**ADA2 DEFICIENCY**  
 Imbalance of the number of macrophages  
 M1 >>> M2


**D**

**UBIQUITINOPATHIES and *NOD2* mutations:**  
 activation of the NF- $\kappa$ B pathway and secretion of proinflammatory cytokines

**C**

**INTERFERONOPATHIES:**  
 Increase of *IFN* gene expression inducing inflammation


INF



**A****Cutaneous features****Livedo +++**





Ulcers / Necrosis +




Arthromyalgia





**Neurologic features**Ischemic stroke / TIA  
Hemorrhagic stroke

Splenomegaly

Abdominal pain /diarrhea

**B****C****D****E****F****G**





**Table 1. Orientation of AID from clinical, biological or histological main features.**

Main clinical, biological or histological features	Presence in the four historical hereditary recurrent fevers	Presence in other AID
<b>Main cutaneous or mucosal features</b>		
Urticaria	<i>NLRP3-associated autoinflammatory disease (NLRP3-AID)</i> <i>MVK</i>	<i>NLRP12-associated autoinflammatory disease (NLRP12-AID)</i> <i>NLRP4</i> <i>PLAID (PLC-gamma2)</i> <i>Schnitzler's syndrome</i>
Neutrophilic dermatosis	TRAPS ( <i>TNFRSF1A</i> )	PAAND ( <i>MEFV</i> ) DIRA ( <i>IL-1 RN</i> ) DITRA ( <i>IL-36 RN</i> ) PAPA Syndrome ( <i>PSTPIP1</i> ) ORAS Syndrome ( <i>OTULIN</i> ) Majeed Syndrome ( <i>LPIN2</i> ) Proteasome associated diseases= CANDLE ( <i>PSMB8</i> ) Aseptic abscesses syndrome
Aphthous ulcer	MKD ( <i>MVK</i> ) CAPS ( <i>NLRP3</i> )	Familial cold urticaria with <i>NLRP12</i> mutations ( <i>NLRP12</i> ) Majeed Syndrome ( <i>LPN2</i> ) A20 haploinsufficiency ( <i>TNFAIP3</i> ) NOD2 associated autoinflammatory diseases ( <i>NOD2</i> ) PFAPA PAPA-like ( <i>PSTPIP1</i> )
Erythema	FMF ( <i>MEFV</i> ) TRAPS ( <i>TNFRSF1A</i> ) Familial cold urticaria with <i>NLRP12</i> mutations ( <i>NLRP12</i> )	NLRP4-MAS ( <i>NLRP4</i> ) TNFRF11A- receptor associated periodic syndrome ( <i>TNFRF11A</i> ) Systemic juvenile arthritis ( <i>LACC1</i> ) Adult and children onset Still disease
Pustulosis and/or psoriasis		PAAND ( <i>MEFV</i> exon 2) DIRA ( <i>IL-1 RN</i> ) DITRA ( <i>IL-36 RN</i> ) PAPA et PAMI ( <i>PSTPIP1</i> ) CAMP5 ( <i>CARD14</i> )
Pityriasis rubra pilar		PAAND ( <i>MEFV</i> exon 2) PAID ( <i>PSTPIP1</i> ) Nicastrine associated diseases ( <i>NCSTN</i> ) Aseptic abscesses syndrome
Acne, sterile abscess Pyoderma gangrenosum, And/or hidradenitis suppurativa		NAID ( <i>NOD2</i> ) Blau Syndrome ( <i>NOD2</i> )
Eczema, atopic dermatosis		Interferonopathies ADA2 deficiency ( <i>ADA2</i> )
Livedo	0	Proteasome-associated autoinflammatory syndrome ( <i>PRAAS</i> )
Lipodystrophy		H syndrome ( <i>SLC29A3</i> )
Hyperpigmentation and hypertrichosis		
<b>Digestive features</b>		
	FMF ( <i>MEFV</i> ) <i>MVK</i> <i>NLRP3</i> TRAPS ( <i>TNFRSF1A</i> )	NLRP4-MAS ( <i>NLRP4</i> ) Ubiquitinopathies ( <i>A20, Otulin</i> )
<b>Neurological features</b>		
Chronic recurrent meningitis	CAPS (CINCA, MWS) <i>NLRP3</i> MKD ( <i>MVK</i> )	<i>NLRP4</i>
Strokes		Interferonopathies SFID ( <i>TRNT1</i> ) ADA2 deficiency ( <i>ADA2</i> )
<b>Hematological or immunological abnormalities</b>		
Immunodeficiency	0	PLAID ( <i>PLC-gamma2</i> ) Ubiquitinopathies ( <i>HOIL-1</i> ) SFID ( <i>TRNT1</i> ) ADA2 deficiency ( <i>ADA2</i> ) PFIT ( <i>WDR1</i> )
Cytopenia	0	PFIT ( <i>WDR1</i> ) SFID ( <i>TRNT1</i> ) NLRP4-MAS Majeed Syndrome ( <i>LPIN2</i> )
Autoantibodies	0	Ubiquitinopathies ( <i>A20, ORAS</i> ) NAIAD ( <i>NLRP1</i> ) PLAID ( <i>PLC-gamma2</i> ) Interferonopathies ADA2 deficiency ( <i>ADA2</i> )
Monoclonal immunoglobulin	0	Schnitzler's syndrome
<b>Histological features</b>		
Granuloma	0	Blau syndrome ( <i>NOD2</i> ) ADA2 deficiency ( <i>ADA2</i> ) PLAID et APLAID ( <i>PLC-gamma2</i> ) ORAS Syndrome ( <i>OTULIN</i> )
Vasculitis	FMF ( <i>MEFV</i> )	PAAND ( <i>MEFV</i> ) A20 haploinsufficiency ( <i>TNFAIP3</i> ) ORAS ( <i>OTULIN</i> ) PAPA ( <i>PSTPIP1</i> ) ADA2 deficiency ( <i>ADA2</i> ) SAVI Syndrome ( <i>TMEM173</i> )



Table 2. Main characteristics of HA20 with autoinflammatory features from literature.

Characteristics	Details	Frequency (%)
<b>Epidemiology</b>	Geographic origin :	
	- Japan	60%
	- Europe	30%
	- Turkey	10%
	Sex ratio : women	68.6%
<b>Age at onset</b>	Minimum 2 months Maximum 20 years	92% in childhood
<b>Crisis length</b>	Between 3 to 14 days. Sometimes persistent symptoms	
<b>Crisis recurrences</b>	Between 1 to 12/year	
<b>Main clinical symptoms</b>	Buccal aphtae ulcer	88%
	Recurrent fever	78%
	Genital aphtae ulcer	68%
	Digestive features (pain/diarrhea)	57%
	Cutaneous lesions	45%
	Arthromyalgia	31%
	Ocular symptoms	10%
	Cardiovascular features	8%
	Immunodeficiency	6%
	Central nervous system features	4%
<b>Autoantibodies</b>	(n=17) especially: - antithyroidis (n=8) - antinuclear(n=4)	33%
<b>Efficient treatments</b>	- Colchicine (n=8) - Infliximab (n=6) - Anakinra (n=2) and adalimumab (n=2)	15.7% 11.7% 8%

**Table 3. A diagnostic-check-list for AID.**

<b>Elements to investigate</b>	<b>Details to check</b>	<b>Most famous elements that usually orientate toward one of the most frequent AID</b>
<b>1-Familial history</b>	Mediterranean origin	FMF
	Dominant transmission	CAPS, TRAPS, HA20
	Recessive transmission	MKD, DADA2
	Sporadic case	PFAPA, Still disease
<b>2-Personal history</b>	Age at onset - early (birth or during the firsts years) - during or after childhood	CAPS, MKD, DADA2
	Duration of crisis	FMF: 2 to 4 days MKD: 5 to 8 days TRAPS: 7 to 21 days Still disease: 15 to more than 30 days
<b>3-Clinical symptoms</b>	Digestive (abdominal pain)	FMF, TRAPS, MKD
	Cutaneous (urticaria, erythema, aphtae, livedo)	urticaria: CAPS
	Rheumatic: arthromyalgia	livedo: DADA2
	Neurological (meningitis)	bipolar aphtous: HA20
	Ocular (conjunctivitis, uveitis)	Still disease, TRAPS
	ENT (hearing loss)	CAPS CAPS
	Recurrent infections	CAPS DADA2
<b>4-Peripheral inflammation</b>	CRP level and neutrophil cell count elevation during attacks	All AID (except interferonopathies)
	Normal rate after attack resolution	
<b>5-Existence of diagnostic criteria</b>	Only in some AID	FMF CAPS NOD2 AID Schnitzler disease Still disease